

Synthesis of Fusion-Isomeric Imidazopyridines and Their Evaluation as Inhibitors of *syn*- and *anti*-Protonating Glycosidases


by Narinder Mohal and Andrea Vasella*

Laboratorium für Organische Chemie, ETH-Hönggerberg, HCI, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich

The *galacto*- and *gluco*-configured imidazopyridines **4** and **5** were synthesised as potential inhibitors of *syn*-protonating β -glycosidases. Methyl α -D-lyxopyranoside (**9**) was transformed into the 3,4-anhydro- β -L-ribose **16**, which, upon treatment with Et_2AlCN , gave the nitrile **17** (76–85%). Reaction of **17** with the dimethyl aluminate of aminoacetaldehyde dimethyl acetal led directly to the branched chain *lyxo*-configured imidazole **27** (53%) that was hydrolysed to an equilibrating mixture of **4** and **28–30**. Oxidoreduction of **27** provided the *arabino*-configured imidazole **42** (ca. 48% from **27**). Hydrolysis of **42** led to the mixture **5/45** (63–90%). *anti*-Protonating β -galactosidases and β -glucosidases (families 1 and 2) were only weakly inhibited by **4/28–30** and **5/45**, respectively. Also the *syn*-protonating cellulase (Cel7A) was weakly inhibited by the monosaccharide mimics **5/45**, suggesting either that monosaccharide mimics are too small to inhibit Cel7A, or that fusion isomeric tetrahydroimidazo[1,2-*a*]pyridines are not a suitable scaffold for the inhibition of *syn*-protonating glycosidases.


Introduction. – Selective inhibitors of *anti*- and *syn*-protonating glycosidases [1] will be useful to specify the (relative) position of the catalytic acid; they also have the potential of being highly selective. Of particular interest are complementary inhibitors of *syn*- and *anti*-protonating glycosidases possessing a common scaffold, as this would facilitate a comparative interpretation of the inhibitory activity. However, there are as yet no inhibitors selective for *syn*-protonating (α - or β -) glycosidases.

The *anti*- and *syn*-protonating glycosidases differ by the trajectory of the proton transfer from the catalytic acid AH to the glycosidic oxygen (**I** and **II**) and the tetrahydroimidazo[1,2-*a*]pyridines of type **1** are strong (about nanomolar) inhibitors of



anti-protonating β -glycosidases, interacting in a cooperative way with the catalytic acid and the catalytic base of the enzyme [2–17]. Tetrahydroimidazo[1,5-*a*]pyridines of type **2** [18–24] do not possess a ‘glycosidic heteroatom’ – a heteroatom that is located (more or less) in the same place as O–C(1) of glycosides – that could interact with the catalytic acid AH of either an *anti*- or a *syn*-protonating glycosidase. Not unexpectedly, these imidazoles are relatively weak glycosidase inhibitors. We wondered about the isomeric tetrahydroimidazo[1,2-*a*]pyridines of type **3**. These isomers do not have a ‘glycosidic heteroatom’ either, but N(1), although not ideally located, could interact with the catalytic acid AH of a *syn*-protonating glycosidase, provided the catalytic acid is (sufficiently) flexible, as it has indeed been advocated [25–27]. This consideration led us to first synthesise the monosaccharide-derived *galacto*- and *gluco*-configured imidazoles **4** and **5** (Scheme 1). These imidazoles will presumably exist in equilibrium with their open-chain aldehyde tautomers **4a** and **5a**, and be configurationally labile at HO–C(5). We were, however, confident that **4** and **5** would be sufficiently stable to be isolated and tested, and that, upon binding to a specific glycosidase, they would adapt their configuration at C(5) to the one of the preferred substrate.

Scheme 1




The plan for the synthesis of the imidazopyridines **4** and **5** is outlined in Scheme 1. It is based on the assumption that glycoside hydrolysis of the branched-chain imidazolyl glycoside **6** or **7** is followed by equilibration of the resulting hemiacetals and corresponding hydroxyaldehydes **4a** and **5a**, and that further equilibration will lead to the desired tetrahydroimidazopyridines **4** and **5**. The branched-chain glycoside **6** should be obtained by regioselective ring opening of the known anhydrosugar- β -L-pyranoside **8** [28] and transformed into its isomer **7**.

Results and Discussion. – 1. *Synthesis of the galacto-Imidazole 4.* Methyl α -D-lyxopyranoside (**9**) [28] was obtained in a yield of 77% by Fischer glycosidation of D-lyxose with AcCl in anhydrous MeOH (Scheme 2). This controlled generation of HCl led to results that compare favourably with those of known procedures [28][29]. Isopropylidenation of **9** [30] with acetone and Amberlyst-15 resulted consistently in yields of at least 85–90% of **10**. Tosylation to **11** [29] was followed by hydrolysis to the hydroxy toluenesulfonate **12**. Treatment of **12** with *t*-BuOK in THF provided the epoxide **8** in a maximal yield of 83–92% (33–40% from D-lyxose; 10–30-mmol scale). Lower yields resulted from using MeONa in MeOH [28].

The epoxide **8** in CDCl₃ adopts almost exclusively the oH_1 conformation, as evidenced by $J(1,2) = 2.8$ Hz. The energy difference between the 1H_o and oH_1

Scheme 2



a) Amberlyst-15, 4-Å mol. sieves, Me₂CO. b) TsCl, pyridine; 84% from **9**. c) 80% aq. AcOH; 93%. d) ^tBuOK THF; 83%. e) Et₂AlCN, Et₂O. f) Amberlyst-15, Me₂CO, 4-Å mol. sieves; 17% of **15** and 20% of **13** from **8**. g) TIPSOTf (TIPS = (i-Pr)₃Si), 2,6-lutidine; 80–96%. h) Et₂AlCN, Et₂O; 76–85%.

conformers is small, and the barriers for their interconversion are low [31], so that *trans*-diaxial opening of the oxirane **8** is not sufficient to control regioselectivity. Ammonia and amines attack **8** preferentially at the less hindered C(4) [32], and treatment of **8** with HBr provided methyl 4-bromo-4-deoxy-D-lyxoside [28]. However, all attempts to introduce an imidazolyl moiety at C(4) (or at C(3)) by treating **8** with protected imidazolyl anions failed under a variety of conditions [11–13][33]. We, therefore, planned to introduce a CN group, and to transform it into the imidazolyl moiety *via* the corresponding amide and thioamide [2][4][6–8][34–36]. Treating the epoxide **8** with Et₂AlCN [37] resulted in an inseparable 1:1 mixture of the *trans*-hydroxy carbonitriles **13** and **14** (66%). Treatment of this mixture with acetone in the presence of Amberlyst-15 transformed **14** to **15**, which was readily separated from **13**; this isopropylidenation establishes the constitution of **13** and **14**, and the configuration of **13** (Scheme 2). Unlike in a related favourable case [38], complexation of Et₂AlCN with MeO–C(1) led neither to (regioselective) intramolecular delivery of cyanide nor to a sufficiently biased conformation. We then speculated that protection of HO–C(2) of **8** with the bulky (i-Pr)₃Si (TIPS) group would prevent the formation of a H-bond from HO–C(2) to the incipient oxyanion center, resulting from attack at C(3), that the TIPSO group would prefer a pseudoequatorial orientation, favour the ¹H₀ conformation, and lead to a preferential attack of cyanide at C(4). The desired silyl ether **16** was readily obtained and characterised as a *ca.* 1:1 mixture of the ²H₁ and ¹H₀ conformers by *J*(1,2) = 4.6 Hz. Opening of the oxirane ring of **16** by Et₂AlCN provided almost

exclusively **17**¹⁾. The minor regioisomer resulting from attack at C(3) of **16** was isolated in maximal 5% and desilylated to **13**. An alternative substitution of **16** with KCN in DMSO was inefficient and proceeded with concomitant *O*-desilylation; it led regioselectively to **14**.

The ¹H-NMR spectrum of **13** in CD₃OD and in CDCl₃ displayed a characteristic H–C(3) *t* with $J(2,3) \approx J(3,4) \approx 7.8$ Hz, evidencing that it is mostly adopting the ¹C₄ conformation. The H–C(4) of **17** resonates at 3.01 ppm as a *td* with $J(3,4) = J(4,5_{\text{ax}}) = 9.6$; also $J(4,5_{\text{eq}}) = 4.5$ Hz. $J(1,2) = 2.4$, $J(2,3) = 3.0$ Hz are in agreement with a preferred ⁴C₁ conformation. The data are consistent with coupling constants calculated for the ⁴C₁ conformer of α -D-lyxose ($J(1,2) = 2.1$, $J(2,3) = 3.1$, $J(3,4) = 8.8$, $J(4, 5_{\text{eq}}) = 5.8$, $J(4, 5_{\text{ax}}) = 10.5$ Hz) [40], which is more stable than the ¹C₄ conformer by *ca.* 0.9 kcal/mol. These interpretations are supported by MM3 calculations [40]. Crystalline methyl α -D-lyxopyranoside also adopts the ⁴C₁ conformation [41].

According to a literature precedent [38], **17** was transformed to the amides **18** and **19** in ratios varying from 3:2 to 7:3, reflecting the migration of the TIPS group [42] (*Scheme 3*). Desilylation of the mixture **18/19** (TBAF · 3 H₂O)²⁾ provided **20** in > 95% yield. Isopropylidenation of **20** gave **21** besides *ca.* 10% of the 1,3-oxazin-4-one **22**; formation of an oxazinone under such conditions appears to be unprecedented. Lawesson's reagent transformed the amide **21** to the thioamide **23** (84%). Treatment of **23** with aminoacetaldehyde dimethyl acetal under a variety of conditions yielded neither an amidine nor an imidazole, but transformed **23** back to the nitrile **15**. We also attempted to synthesise an imidazole *via* the acetylated amide **24** and thioamide **25**. Treatment of **25** with aminoacetaldehyde dimethyl acetal in the presence of a variety of thiophilic reagents such as Hg(OAc)₂, HgO, and PbO afforded only the acetylated carbonitrile **26**. No reaction occurred in the absence of thiophilic reagents up to a temperature of 110°. An attempt to transform the carbonitriles **15**, **17**, and **26** to amidines by aminolysis of the corresponding nitrilium salts, generated under conditions of the *Pinner* reaction [43] or in the presence of a *Lewis* acid [44][45], and further to imidazoles also failed, as did the formation of an imidazole ring from the amides **21** or **24**.


Unexpectedly, however, the imidazole **27** was obtained (53%) in an attempt at transforming the carbonitrile **17** into the corresponding amidine by treatment with the aluminum amide derived from aminoacetaldehyde dimethyl acetal and Me₃Al (1:1), as suggested by the work of *Weinreb* and co-workers [46], *Garigipati* [47], and *Moss et al.* [48] (*Scheme 4*). This unprecedented one-pot synthesis of an imidazole from a carbonitrile is, however, not general and depends on the presence of the vicinal HO–C(3) group³⁾. The lyxopyranoside **27** was hydrolysed with 20% aq. HCl in 80% aq. AcOH at 110° to provide a *ca.* 60:8:14:18 equilibrium mixture of the *galacto*-

¹⁾ In an exploratory experiment, **16** was treated with Me₃SiCN in the presence of activated MgO or CaO [39]; this also led to regioselective opening at C(4) with simultaneous silylation of HO–C(3). The activation of MgO or CaO was essential to secure good yields. We thank *Florian Kleinbeck* for performing this experiment.

²⁾ Less-satisfactory conditions include heating with 50% aq. AcOH and treatment with 20% aq. HCl in EtOH at 23°, the poor yield under hydrolysis conditions reflecting partial glycoside hydrolysis.


³⁾ A similar treatment of a few representative carbonitriles lacking a corresponding OH group led (in high yields) to amidines.

Scheme 3



a) 30% H₂O₂, K₂CO₃, Me₂CO/H₂O 3:2; 86–95%. b) TBAF · 3 H₂O, THF; 85–95%, or 50% aq. AcOH; 50%, or 20% aq. HCl/EtOH 1:1; 50%. c) Amberlyst-15, Me₂CO, 4-Å mol. sieves; 81% of **21** and 12% of **22**. d) Lawesson's reagent, toluene; 84% of **23**; 76% of **25**. e) NH₂CH₂CH(OMe)₂, Hg(OAc)₂, THF; 86% of **15**; > 95% of **26**. f) Ac₂O, 4-(dimethylamino)pyridine (DMAP), pyridine; 65%.

Scheme 4



a) Me₃Al, NH₂CH₂CH(OMe)₂, toluene; 46–53%. b) 20% aq. HCl, 80% aq. AcOH; 70%. c) NaCNBH₃, MeOH/AcOH; 90%. d) Et₃SiCl, 2,6-lutidine, pyridine; 16% of **32**, 22% of **33**, 8% of **34**.


configured fused imidazole **4**, its *talo*-isomer **28**, and the branched-chain anomeric lyxopyranoses **29** and **30**. The desired *galacto*-imidazole **4** was the main component of this mixture between pH 5.5 and 8. In agreement with the interpretation of the complex NMR spectra of the hydrolysis products, reduction of the mixture **4/28–30** with NaCNBH₃ provided the tetrol **31** in high yields (90%). Triethylsilylation of **4/28–30** and flash chromatography provided the *galacto*-configured imidazoles **32** and **33**, and the *talo*-configured imidazole **34** in 16, 22, and 8% yield, respectively. As expected, desilylation of **32** and **34** with aq. HCl in CD₃OD at 24° for 36 h led in each case to the mixture **4/28–30**.

The H–C(4') and H–C(5') of the imidazole moiety of **27** give rise to a characteristic br. s at 6.97 ppm. The preferred ⁴C₁ conformation of **27** agrees well with $J(1,2) = 2.2$, $J(2,3) = 3.0$, $J(3,4) = 9.9$, $J(4,5_{ax}) = 10.5$, and $J(4,5_{eq}) = 4.8$ Hz. The C(4') and C(5') signals of the imidazole moiety of **27** appear as two broad ds at 127.83 and 115.19 ppm, respectively. Upon addition of a catalytic amount of AcOH they appear as a sharp d at 119 ppm. The constitution of **4** is evidenced by the characteristic s of C(8a) at 145.70, and by ds of C(2), C(3), and C(5) at 127.42, 118.23, and 81.58 ppm, respectively. $J(5,6) = 7.2$, $J(6,7) = 1.5$, $J(7,8) = 3.6$ Hz are in agreement with a ⁷H₆ as the predominant conformation and with the *galacto*-configuration of **4**. The tetrakis(triethylsilyl) ether **32** adopts the ⁷H₆ conformation in CDCl₃ solution in agreement with $J(5,6) = 6.9$, $J(6,7) = 1.5$, $J(7,8) = 3.0$ Hz. In CD₃OD solution, it exists as mixture of the ⁷H₆ and ⁶H₇ conformers with a predominant contribution from the ⁷H₆ conformer as indicated by $J(5,6) = 5.4$, $J(6,7) = 1.5$, $J(7,8) = 4.2$, $J(8,CH_a) = 7.2$, $J(8,CH_b) = 5.7$, and $J(CH_a,CH_b) = 9.9$ Hz. The *galacto*-alcohol **33** exists as ca. 2:1 mixture of ⁷H₆ and ⁶H₇ conformers, respectively, as evidenced by $J(5,6) = 4.5$, $J(6,7) = 2.1$, $J(7,8) = 6.3$, $J(8,CH_a) = 5.4$, $J(8,CH_b) = 8.4$, and $J(H-C(7),OH) = 4.2$ Hz. The ⁷H₆ conformation and *talo*-configuration of **34** is in agreement with $J(5,6) = 3.9$, $J(6,7) = 2.1$, $J(7,8) = 4.2$, $J(8,CH_a) = 4.2$, $J(8,CH_b) = 10.8$ Hz, and a $J(5,7)$ w-coupling of 1.8 Hz. The large value of $J(H-C(7),OH) = 7.2$ Hz for **34** indicates a H-bond between HO–C(7) and Et₃SiO–C(5).

2. Synthesis of the gluco-Imidazole 5. Oxidation–reduction or inverting substitution at C(3) of **17** and subsequent transformations should provide the desired imidazole **5**, but both transformations proved difficult (*Scheme 5*). Oxidation of **17** with Dess–Martin's periodinane [49], PCC, tetrapropylammonium perruthenate (TPAP) and NMO [50], or with DMSO/(COCl)₂ and Et₃N [51]) failed to provide the ketone **35**. Mitsunobu substitution with 4-nitrobenzoic acid [52] did not lead to a nitrobenzoate, but partially transformed **17** into a complex mixture. The readily prepared triflate **36** was stable to chromatography on silica gel and to prolonged storage at –20°, but reacted with NaNO₂, AcONa, AcOK, AcOCs, or Bu₄NOAc in DMF to provide only the unsaturated carbonitrile **38** without any indication of a substitution product. The corresponding methanesulfonate **37** was either not affected under the same conditions of attempted substitution, or also transformed to **38**, presumably on account of the acidity of H–C(4). As H–C(4) of imidazolyl analogues should be considerably less acidic, we used the (*tert*-butoxy)carbonyl (Boc) derivative **39** of **27** as the starting material.

While attempted substitution of HO–C(3) of **39** under Mitsunobu conditions either did not affect the starting material or gave intractable mixtures, Dess–Martin

Scheme 5



oxidation [49] gave readily the ulopyranoside **40** (58%) besides the doubly epimerised **41** (10%), and proved superior to oxidation under *Swern* conditions [51]. The ketone **41** was formed only during chromatography, as evidenced by the ^1H -NMR spectra of the crude, and its formation may be rationalised by a reversible elimination–addition of MeOH.

Reduction of **40** with NaBH_4 in the presence of $\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$ [53] gave exclusively the α -D-arabinopyranoside **42** (80%), presumably as the consequence of the complexation of Ce^{III} with the $\text{C}(3)=\text{O}$ and $\text{MeO}-\text{C}(1)$ groups affecting the conformation of the pyranose ring and preventing the axial approach of hydride. Reduction of **40** with $\text{NaBH}_4/\text{MeOH}$ gave a nearly 1:1 to 2:3 mixture of the *lyxo*-configured **39** and the *arabino*-configured **42**. Workup and chromatography, however, yielded typically 46% of **39** and 26% of **42**, and *ca.* 20% of a 4:1 to 9:1 mixture of *tert*-butyl carbonate **43** and

its epimer. The yields and ratio of **39** and **42** reflect the migration of the *N*-Boc group to HO–C(3) of **42** and, considerably more slowly, also of **39**. The migration is catalysed by base; treating pure **42** with Et₃N in MeOH yielded 71% of **43**. A related case of this type of *N,O*-carbonyl exocyclic rearrangement for *N*-carbonyl-oxazolidin-2-ones has been reported [54][55]. To confirm the structure, we reduced **41** with NaBH₄ in MeOH to the β-D-xylopyranoside **44** (56%).

The ulopyranoside **40** adopts a flattened ⁴C₁ conformation in agreement with $J(1,2) = 1.8$, $J(4,5_{\text{eq}}) = 6.6$, and $J(4,5_{\text{ax}}) = 11.1$ Hz. C(1) of **40** appears as *d* at 104.76, C(3) as *s* at 201.12 ppm. A C(1) *d* at 107.40, and $J(1,2) = 7.5$, $J(4,5_{\text{eq}}) = 6.3$, and $J(4,5_{\text{ax}}) = 11.4$ Hz are consistent with a flattened ⁴C₁ conformation and with the configuration of **41**. The vicinal $J(1,2) \approx 1.2$, $J(2,3) = 3.0$, $J(3,4) = 2.1$, $J(4,5_{\text{eq}}) = 4.0$, $J(4,5_{\text{ax}}) = 11.1$, and a $J(3,5_{\text{eq}})$ *w*-coupling of 1.2 Hz are consistent with the ⁴C₁ conformation and the α-D-*arabino*-configuration of **42**. An intramolecular H-bond from HO–C(3) to N(3') of **42** is evidenced by a *d* ($J = 5.4$ Hz) at 4.95 ppm. In the IR (CHCl₃) spectrum of **42**, the characteristic band at 3505 cm⁻¹ for HO–C(3) did not change upon dilution (0.1M, 0.17M, 0.51M, 0.85M, 1.27M, 1.76M), evidencing an intramolecular H-bond. The disappearance of two *ds* at 7.34 ($J(4',5') = 1.8$, H–C(5')) and 6.86 ppm ($J(4',5') = 1.8$, H–C(4')), and the appearance of two br. *s* at 7.0 (H–C(4')), and 6.96 ppm (H–C(5')) in the ¹H-NMR spectrum of **43** evidences the migration of the *N*-Boc group to HO–C(3). A ca. 1:1 mixture of ⁴C₁ and ¹C₄ conformers of **43** is evidenced by $J(1,2) = 4.5$, $J(2,3) = 6.0$, $J(3,4) = 4.2$, $J(4,5_{\text{eq}}) = 4.2$, and $J(4,5_{\text{ax}}) = 6.0$ Hz. The β-D-*xylo*-configuration and the ⁴C₁-conformation of **44** agrees with $J(1,2) = 7.5$, $J(2,3) = 8.7$, $J(3,4) \approx J(4,5_{\text{ax}}) \approx 10.5$, $J(4,5_{\text{eq}}) = 4.2$ Hz, and the downfield shift of C(1) at 105.46 ppm. $J(\text{H} - \text{C}(3), \text{HO}) = 3.6$ Hz agrees with an intramolecular H-bond to the equatorial imidazolyl or TIPSO group.

Hydrolysis of **42** (20% aq. HCl in 80% aq. AcOH) at 110° provided a ca. 1:1 equilibrium mixture of the D-*gluco*-configured **5** and its D-*manno*-isomer **45**, accounting for more than 95% of product. In keeping with the structure of **5/45**, reduction with NaCNBH₃ provided the tetrol **46** (66%). Silylation of **5/45** and chromatography gave the D-*manno*-imidazole **47** (27%) and the D-*gluco*-imidazole **48** (16%).

The D-*gluco*-configuration and predominant ⁷H₆ conformation of **5** is evidenced by $J(5,6) = 7.2$, $J(6,7) \approx J(7,8) \approx 9.3$ Hz; the *manno*-configuration of **45**, and its (prepondering) ⁶H₇ and ⁷H₆ conformations are in agreement with $J(5,6) = 3.6$, $J(6,7) = 8.4$, and $J(7,8) = 7.5$ Hz. The *gluco*-configured silyl ether **48** adopts a ⁶H₇ conformation with *pseudo*-axial silyloxy and (silyloxy)methyl groups as evidenced by $J(5,6) = 1.8$, $J(6,7) = 3.6$, $J(7,8) \approx 1.2$, $J(8, \text{CH}_a) \approx 10.8$, $J(8, \text{CH}_b) = 5.4$ Hz, and a *w*-coupling of $J(5,7) \approx 0.9$ Hz. There is precedent for the preferred axial orientation of silyloxy groups [56–63]. The *manno*-imidazole **47** adopts preferentially the B_{5,8} conformation in accordance with $J(5,6) = 1.8$, $J(6,7) = 5.1$, $J(7,8) \approx 1.2$, $J(8, \text{CH}_a) = 5.1$, and $J(8, \text{CH}_b) = 10.5$ Hz.

Inhibition Studies. Exploratory inhibition experiments indicate that the D-*galacto*/D-*talo* and D-*lyxo*-configured imidazoles **4/28–30**, and D-*gluco*/D-*manno*-configured imidazoles **5/45** respectively, inhibit – at best – very weakly the *anti*-protonating β-glycosidases from family 1 and 2 (*IC*₅₀ in the mM range). The mixture **4/28–30** containing the D-*galacto*-imidazole **4** was assayed against β-galactosidases from *E. coli* (family 2 [64]), bovine liver, and *A. oryzae* [65]). The β-galactosidases from *E. coli* and bovine liver were not inhibited by **4/28–30** up to a concentration of 7 mM, while the β-

galactosidase from *A. oryzae* was weakly inhibited ($IC_{50} \approx 1$ mM, $[S] = 0.56$ mM, 50 mM AcONa buffer, pH 4.9).

The β -glucosidase from *Caldocellum saccharolyticum* (family 1) and the β -glucosidases from sweet almonds were weakly inhibited by the D-glucob-manno mixture **5/45** ($IC_{50} \approx 500$ μ M, $[S] = 2.02$ mM, 50 mM AcONa buffer, pH 4.9) and ($IC_{50} \approx 760$ μ M, $[S] = 2.45$ mM, 100 mM phosphate buffer, pH 6.9), respectively. Not unexpectedly, the monosaccharide imidazoles **5/45** inhibited the *syn*-protonating cellulase Cel7A from *T. reesei* (family 7) only weakly ($IC_{50} \approx 24$ mM at 50°; no inhibition up to 7.2 mM at 30°, $[S] = 0.722$ mM, 50 mM AcONa buffer, pH 4.9); a significant inhibition requires at least a disaccharide analogue [66–68].

We thank the Swiss National Science Foundation and F. Hoffmann-La Roche AG, Basel, for generous support. We thank Dr. B. Bernet for checking the *Exper. Part*, and Dr. B. Bernet and Dr. Chepuri Venkata Ramana for valuable discussions. We thank Dr. Anu Koivula, VTT Biotechnology and Food Research, VTT, Espoo, Finland, for a generous gift of Cel7A.

Experimental Part

General. All reactions were carried out under N₂ unless specified otherwise. THF and Et₂O were distilled over Na/benzophenone, and DMF, MeCN, and CH₂Cl₂ were distilled over CaH₂. TLC: *Alugram*[®] silica gel 60 GF₂₅₄ plates; detection by heating with 'mostain' (400 ml of 10% aq. H₂SO₄ soln., 20 g of (NH₄)₆Mo₇O₂₄·6 H₂O, 0.4 g of Ce(SO₄)₂) or 10% aq. H₂SO₄ soln. or 2% KMnO₄ in 4% aq. NaHCO₃ soln. Flash chromatography (FC): silica gel *Fluka* 60 (0.04–0.063 mm). M.p.: uncorrected. Optical rotations: 1-dm cell at 25°, 589 nm. FT-IR spectra: KBr or ca. 2% soln. in CHCl₃; absorption in cm^{–1}. ¹H- and ¹³C-NMR spectra: chemical shifts δ in ppm, referenced at 7.26 ppm for ¹H- and 77.1 ppm for ¹³C-NMR, respectively, for CHCl₃; coupling constant *J* in Hz. MALDI- and HR-MALDI-MS: 2,5-dihydroxybenzoic acid (DHB). β -Galactosidase from bovine liver (3.2.1.23, as lyophilised powder), β -galactosidase from *E. coli* (3.2.1.23, as lyophilised powder), β -galactosidase from *A. oryzae* (3.2.1.23, as lyophilised powder), β -glucosidase from *Caldocellum saccharolyticum* (3.2.1.21, as lyophilised powder), and β -glucosidases from sweet almonds (3.2.1.21, as lyophilised powder), and all nitrophenyl β -D-glycopyranosides were purchased from *Sigma* and used without further purification.

Methyl α -D-Lyxopyranoside (9) [28][30]. To an ice cold soln. of D-lyxose (17.33 g, 115.5 mmol) in anh. MeOH (110 ml) was slowly added AcCl (*Fluka*, > 99%; 1 ml, 14.08 mmol). The resulting soln. (ca. 1% w/v) was heated under reflux for ca. 4 h until disappearance of D-lyxose. The cooled mixture was neutralised with Ag₂CO₃ (ca. 2 g, pH ca. 7), treated with activated charcoal, and filtered through a short plug of *Celite* (2 $\times$ 2 cm). The filtrate (ca. 160 ml, including washings with MeOH) was evaporated. The residue, solidifying upon cooling, was recrystallised in hot AcOEt (50 ml) to give pure **9** (14.6 g, first crop, 77%). Colourless solid. *R*_f (CHCl₃/MeOH 4:1) 0.48. M.p. 107.4–108° ([69]: 108–109°). $[\alpha]_D^{25} = +55.2$ (*c* = 0.62, H₂O). IR (KBr): 3302s, 3200s, 2992m, 2968s, 2921s, 2876s, 2840m, 1464s, 1454s, 1384m, 1352s, 1150s, 1128s, 1106s, 1060s, 1013s, 971s, 879s, 848s, 776w. ¹H-NMR (300 MHz, CD₃OD): 4.55 (*d*, *J* = 3.6, H–C(1)); 3.76–3.62 (*m*, H–C(2), H–C(3), H–C(4), H_{eq}–C(5)); 3.39 (*dd*, *J* = 11.4, 8.4, H_{ax}–C(5)); 3.30 (*s*, MeO). ¹³C-NMR (75 MHz, D₂O): 102.01 (*d*, C(1)); 71.39 (*d*, C(3)); 70.21 (*d*, C(2)); 67.65 (*d*, C(4)); 63.28 (*t*, C(5)); 56.15 (*q*, MeO). Anal. calc. for C₆H₁₂O₅ (164.16): C 43.90, H 7.37; found: C 44.01, H 7.31.

Methyl 2,3-O-Isopropylidene- α -D-lyxopyranoside (10) [28][29]. To a soln. of **9** (8.97 g, 54.70 mmol) in anh. acetone were added powdered molecular sieves (4 Å; 11.21 g) and *Amberlyst-15* (H⁺ form, 807 mg). The resulting suspension was stirred at 23° for 4 h (consumption of **9**), and filtered through a short plug of *Celite* (3.8 ϕ $\times$ 4 cm; washing with additional 100 ml of acetone). Evaporation of the combined filtrate and washings gave **10** as viscous oil (11.4 g, quant.), which solidified upon storage. It was used for the next step without any further purification. A pure sample of **10** was obtained by FC (hexane/AcOEt 3:1). Colourless solid. *R*_f (hexane/AcOEt 3:2) 0.55. M.p. 51.4–52.6° ([29]: 40–41°; [28]: 49–52°). $[\alpha]_D^{25} = +48.3$ (*c* = 0.8, EtOH). IR (2%, CHCl₃): 3580w (sh), 3450w, 2992w, 2938w, 2839w, 1602w, 1450w, 1384m, 1374m, 1164m, 1140m, 1095s, 1073s, 1009s, 982m, 954m, 908w, 871w, 854m. ¹H-NMR (300 MHz, CDCl₃): 4.63 (*d*, *J* = 3.0, H–C(1)); 4.20 (*dd*, *J* = 6.0, 4.8, H–C(3)); 4.10 (*dd*, *J* = 6.0, 2.7, H–C(2)); 3.82–3.76 (*m*, addn. of D₂O $\rightarrow$ change, H–C(4), H_{eq}–C(5)); 3.67 (*dd*, *J* = 12.9, 6.9, H_{ax}–C(5)); 3.44 (*s*, MeO); 3.18 (*d*, *J* = 7.5, exchanged with D₂O, HO–C(4));

1.49, 1.34 (2s, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 109.51 (s, Me₂C); 99.88 (d, C(1)); 77.36 (d, C(3)); 74.45 (d, C(2)); 63.29 (t, C(5)); 62.29 (d, C(4)); 55.58 (q, MeO); 27.69, 25.73 (2q, Me₂C). Anal. calc. for C₉H₁₀O₅ (204.22): C 43.90, H 7.37; found: C 44.01, H 7.31.

Methyl 2,3-O-Isopropylidene-4-O-[(4-methylphenyl)sulfonyl]-α-D-lyxopyranoside (11) [28][29]. A soln. of **10** (11.40 g, 55.88 mmol) in dry pyridine (14 ml) was treated with TsCl (15.34 g, 80.46 mmol). The resulting thick slurry was stirred at 23° for 22 h, diluted with AcOEt (150 ml), washed with 10% aq. HCl (2 × 25 ml), H₂O (2 × 25 ml), and brine (25 ml), dried (Na₂SO₄), and evaporated. FC (ca. 150 g of silica gel; ca. 300 ml of hexane/AcOEt 13:7) and two crystallisations from CH₂Cl₂/hexane gave **11** (16.45 g, 84% from **9**). Colourless solid. *R*_f (hexane/AcOEt 13:7) 0.66. M.p. 105–106° ([29]: 105–106°). $[\alpha]_D^{25} = -14.8$ (c = 0.91, EtOH) ([29]: $[\alpha]_D^{25} = -18.3$ (c = 0.91, EtOH)). IR (CHCl₃): 3028w, 2992w, 2938w, 1599w, 1451w, 1446w, 1375s, 1308w, 1176m, 1140m, 1095s, 1019s, 1017s, 995m, 962w, 925m, 830s. ¹H-NMR (300 MHz, CDCl₃): 7.83 (d, *J* = 8.4, 2 arom. H); 7.34 (d, *J* = 8.4, 2 arom. H); 4.71 (d, *J* = 1.5, H–C(1)); 4.39 (ddd, *J* = 9.6, 6.9, 5.1, H–C(4)); 4.14 (dd, *J* = 6.3, 5.4, H–C(3)); 4.04 (dd, *J* = 5.4, 1.5, H–C(2)); 3.77 (dd, *J* = 12.0, 5.1, H_{eq}–C(5)); 3.63 (dd, *J* = 12.0, 9.3, H_{ax}–C(5)); 3.38 (s, MeO); 2.44 (s, Me); 1.25, 1.17 (2s, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 144.92, 133.08 (2s); 129.93 (d, 2 C); 128.2 (d, 2 C); 109.91 (s, Me₂C); 98.66 (d, C(1)); 76.95, 75.59, 74.62 (3d, C(2), C(3), C(4)); 58.54 (t, C(5)); 55.58 (q, MeO); 27.57, 26.29 (2q, Me₂C); 21.84 (q, Me). Anal. calc. for C₁₆H₂₂O₇S (358.41): C 53.62, H 6.19; found: C 53.73, H 6.16.

Methyl 4-O-[(4-Methylphenyl)sulfonyl]-α-D-lyxopyranoside (12) [28][29]. A soln. of **11** (11.18 g, 31.22 mmol) in glacial AcOH (48 ml) was warmed to 100–110°, stirred for 5 min, treated with H₂O (12 ml), and stirred for 25 min at 100–110° when TLC showed completion of the reaction. Evaporation without any further heating gave a solid, which was crystallised from CH₂Cl₂/hexane to give **12** (8.89 g, 89%). Colourless solid. *R*_f (hexane/AcOEt 2:3) 0.28. M.p. 93.4–94.2° ([29]: 94–95°). $[\alpha]_D^{25} = 59.2$ (c = 0.86, EtOH) ([29]: $[\alpha]_D^{25} = 61.21$ (c = 0.88, EtOH)). IR (CHCl₃): 3569m, 3390w (sh), 3038w, 2937w, 2837w, 1598m, 1495w, 1465w, 1446w, 1403m, 1369m, 1177s, 1134s, 1100s, 1060s, 1017s, 976s, 956m, 824s. ¹H-NMR (300 MHz, CDCl₃): 7.82 (d, *J* = 8.4, 2 arom. H); 7.35 (d, *J* = 8.4, 2 arom. H); 4.62 (d, *J* = 2.7, H–C(1)); 4.60 (td, *J* = 8.4, 5.7, H–C(4)); 3.96 (dt, *J* = 8.1, 3.7, addn. of D₂O → dd, *J* = 8.1 3.7, H–C(3)); 3.90 (q, *J* = 3.0, addn. of D₂O → t, *J* = 3.0, H–C(2)); 3.64 (dd, *J* = 11.6, 5.2, H_{eq}–C(5)); 3.58 (dd, *J* = 11.6, 8.8, H_{ax}–C(5)); 3.37 (s, MeO); 2.93 (d, *J* = 3.9, exchanged with D₂O, HO–C(3)); 2.58 (d, *J* = 3.0, exchanged with D₂O, HO–C(2)); 2.46 (s, Me). ¹³C-NMR (75 MHz, CDCl₃): 145.33, 132.86 (2s); 129.98 (d, 2 C); 127.94 (d, 2 C); 100.42 (d, C(1)); 77.25 (d, C(4)); 70.27, 68.85 (2d, C(2), C(3)); 59.78 (t, C(5)); 55.59 (q, MeO); 21.85 (q, Me). HR-MALDI-MS: 341.0668 ([*M* + Na]⁺, C₁₃H₁₈NaO₇S⁺; calc. 341.0665). Anal. calc. for C₁₃H₁₈O₇S (318.34): C 49.05, H 5.70; found: C 48.97, H 5.82.

Methyl 3,4-Anhydro-β-L-ribofuranoside (8) [28]. A mixture of anh. THF (25 ml) in a flame-dried 100-ml two-necked flask and *t*-BuOK (2.77 g, 24.70 mmol), under N₂, was cooled to ca. 3°, and treated with a soln. of **13** (6.45 g, 20.6 mmol) in anh. THF (45 ml) over a period of 15 min. The mixture was stirred for 45 min at 3°. During this time, stirring became sluggish. After dilution with anh. THF (40 ml), the mixture was stirred for 20 min, poured into sat. aq. NH₄Cl soln. (15 ml), and stirred for ca. 30 min. The liquid phase was decanted and filtered through a short pad of Celite (2 φ × 2 cm). The residue was treated with AcOEt (150 ml) and filtered. Evaporation of the combined filtrate and filtration through silica gel (ca. 20 g; ca. 120 ml of hexane/AcOEt 2:3) gave **8** (2.77 g, 92%; homogeneous by ¹H-NMR spectroscopy). An anal. sample was obtained by FC (hexane/AcOEt 3:2). Colourless oil. *R*_f (hexane/AcOEt 11:9) 0.24. M.p. < r.t. $[\alpha]_D^{25} = +542.8$ (c = 1.01, CHCl₃) ([28]: $[\alpha]_D^{25} = +98.6$ (c = 1.4, Me₂CO)). IR (CHCl₃): 3554m, 3027m, 3013m, 2960m, 2946m, 2919m, 2869w, 2839w, 1602w, 1466w, 1448m, 1405m, 1351m, 1327w, 1251m, 1149s, 1096s, 1071s, 1046s, 1017s, 1003m, 985s, 955m, 866s, 845m. ¹H-NMR (300 MHz, CDCl₃): 4.36 (d, *J* = 2.5, H–C(1)); 3.96 (dd, *J* = 13.3, 1.25, H_{eq}–C(5)); 3.90 (br. d, *J* = 13.3, H_{ax}–C(5)); 3.75 (ddd, *J* = 9.9, 4.4, 2.5, addn. of D₂O → dd, *J* = 4.4, 2.5, H–C(2)); 3.49 (t, *J* = 4.4, H–C(3)); 3.39 (s, MeO); 3.34 (ddd, *J* = 4.4, 1.5, 0.9, H–C(4)); 2.66 (d, *J* = 9.9, exchanged with D₂O, HO–C(2)). ¹³C-NMR (75 MHz, CDCl₃): 99.84 (d, C(1)); 64.86 (d, C(2)); 58.06 (t, C(5)); 55.63 (q, MeO); 51.86, 51.57 (2d, C(3), C(4)). Anal. calc. for C₆H₁₀O₄ (146.14): C 49.31, H 6.90; found: C 49.30, H 6.85.

Methyl 3-Cyano-3-deoxy-β-L-xylopyranoside (13) and Methyl 4-Cyano-4-deoxy-2,3-O-isopropylidene-α-D-lyxopyranoside (15). A cooled soln. (ca. –15°) of **8** (557 mg, 3.82 mmol) in anh. Et₂O (10 ml, 0.38M) was slowly treated with ca. 1M soln. of Et₂AlCN (7.5 ml, 7.5 mmol, 1.96 equiv.) in toluene. The mixture was allowed to warm to r. t. and then boiled under reflux for ca. 4 h. After the disappearance of **8**, the mixture was cooled in an ice-bath, treated dropwise (caution: exothermic reaction!) with sat. aq. NH₄Cl soln. (ca. 20 ml), and diluted with AcOEt (50 ml). The org. layer was washed with 10% aq. HCl (20 ml) and H₂O (25 ml), dried (Na₂SO₄), and evaporated. A soln. of the residue was dissolved in hexane/AcOEt 1:2, and passed through a short plug of silica gel (8 g of silica gel; hexane/AcOEt 1:2) to give a mixture of **13** and **14** (421 mg), which could not be separated and was used for the next step without further purification.

A soln. of the above mixture (421 mg, 21.9 mmol, *ca.* 90% pure) in dry acetone (25 ml) was treated with powdered molecular sieves (4 Å; *ca.* 3.2 g) and Amberlyst-15 (H⁺ form, 171 mg), stirred for *ca.* 11 h at 24°, and filtered through a short plug of *Celite* (washings with additional acetone). Evaporation and FC (8 g of silica gel; hexane/AcOEt 7:3 → 1:2) gave **15** (142 mg, 17% from **8**) and **13** (135 mg, 21% from **8**).

Data of 13: Colourless solid. *R_f* (hexane/AcOEt 1:4) 0.57. M.p. 121.4–121.8° (CH₂Cl₂/hexane). $[\alpha]_D^{25} = +85.4$ (*c* = 0.48, CHCl₃). IR (CHCl₃): 3602*m*, 3370*w*, 3018*w*, 2935*w*, 2249*w*, 1449*w*, 1256*w*, 1154*m*, 1101*s*, 1067*s*, 1037*s*, 984*w*, 878*w*, 833*w*. ¹H-NMR (300 MHz, CDCl₃): 4.31 (*d*, *J* = 5.4, H–C(1)); 4.12 (*dd*, *J* = 12.0, 3.9, H_{eq}–C(5)); 4.04 (*m*, addn. of D₂O → change, H–C(4)); 3.72 (*dt*, *J* = 7.8, 5.1, irradiat. at 4.31 → *dd*, *J* = 7.8, 4.8, addn. of D₂O → *dd*, *J* = 7.8, 4.8, H–C(2)); 3.52 (*s*, MeO); 3.43 (*dd*, *J* = 11.7, 6.9, H_{ax}–C(5)); 2.92 (*d*, *J* = 4.8, exchanged with D₂O, HO–C(2)); 2.87 (*t*, *J* = 7.8, H–C(3)); 2.70 (*d*, *J* = 5.7, exchanged with D₂O, HO–C(4)). ¹H-NMR (300 MHz, CD₃OD): 4.08 (*d*, *J* = 7.5, H–C(1)); 3.91 (*dd*, *J* = 11.1, 4.8, H_{eq}–C(5)); 3.80 (*td*, *J* ≈ 10.2, 4.8, H–C(4)); 3.46 (*s*, MeO); 3.42 (*dd*, *J* = 10.5, 7.2, H–C(2)); 3.21 (*dd*, *J* = 11.1, 9.9, H_{ax}–C(5)); 2.64 (*t*, *J* ≈ 10.2, H–C(3)). ¹³C-NMR (75 MHz, CD₃OD): 120.17 (*s*, CN); 106.19 (*d*, C(1)); 70.44, 69.29 (2*d*, C(2), C(4)); 67.73 (*t*, C(5)); 57.25 (*q*, MeO); 44.07 (*d*, C(3)). Anal. calc. for C₇H₁₁NO₄ (173.16): C 48.55, H 6.40, N 8.09; found: C 48.64, H 6.43, N 8.00.

Data of 15: Colourless solid. *R_f* (hexane/AcOEt 4:1) 0.32. M.p. 85.5–85.8° (hexane). $[\alpha]_D^{25} = +9.0$ (*c* = 1.0, CHCl₃). IR (CHCl₃): 3027*m*, 2993*s*, 2938*s*, 2841*w*, 2246*w*, 1602*w*, 1465*w*, 1385*m*, 1375*m*, 1350*w*, 1288*w*, 1245*m*, 1162*m*, 1140*s*, 1128*s*, 1097*s*, 1063*m*, 1018*m*, 980*w*, 956*w*, 893*m*, 850*m*. ¹H-NMR (300 MHz, CDCl₃): 4.87 (*d*, *J* = 1.2, H–C(1)); 4.38 (*dd*, *J* = 8.4, 5.1, H–C(3)); 4.04 (*dd*, *J* = 5.1, 1.2, H–C(2)); 3.78 (*d*, *J* = 7.2, 2 H–C(5)); 3.41 (*s*, MeO); 2.66 (*q*, *J* ≈ 7.8, H–C(4)); 1.54, 1.37 (2*s*, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 118.04 (*s*, C≡N); 110.28 (*s*, Me₂C); 98.40 (*d*, C(1)); 72.88, 72.22, (2*d*, C(2), C(3)); 56.62 (*t*, C(5)); 55.62 (*q*, MeO); 32.29 (*d*, C(4)); 28.28, 26.23 (2*q*, Me₂C). Anal. calc. for C₁₁H₁₅NO₄ (173.17): C 56.33, H 7.09, N 6.57; found: C 56.55, H 7.05, N 6.35.

Methyl 3,4-Anhydro-2-O-(triisopropylsilyl)-β-L-ribofuranoside (16). A soln. of **8** (2.77 g, 18.99 mmol) in anhyd. DMF (5 ml) was treated with 2,6-lutidine (4.4 ml, 37.8 mmol), cooled to 3°, slowly treated with triisopropylsilyl (TIPS) triflate (5.3 ml, 19.65 mmol) over a period of 15 min, and stirred at 3° until disappearance of **8** (*ca.* 3.5 h). The mixture was diluted with AcOEt (100 ml) and washed with 25% aq. CuSO₄ soln. (2 × 25 ml), H₂O (25 ml), and brine (25 ml), dried (Na₂SO₄), and evaporated. FC (*ca.* 65 g of silica gel; hexane/AcOEt 19:1 → 9:1) gave **16** (4.71 g, 76% from **12**). Colourless oil. *R_f* (hexane/AcOEt 17:1) 0.40. M.p. < r.t. $[\alpha]_D^{25} = +98.6$ (*c* = 0.94, CHCl₃). IR (CHCl₃): 3028*w*, 3006*w*, 2945*s*, 2868*s*, 1465*m*, 1390*w*, 1319*w*, 1146*s*, 1122*s*, 1093*w*, 1054*m*, 997*s*, 957*w*, 882*m*. ¹H-NMR (300 MHz, CDCl₃): 4.30 (*d*, *J* = 4.2, H–C(1)); 4.05 (*dd*, *J* = 13.2, 2.4, H_{eq}–C(5)); 3.93 (*dt*, *J* = 13.5, 1.0, H_{ax}–C(5)); 3.92 (*dd*, *J* = 4.5, 3.0, H–C(2)); 3.39 (*br. dd*, *J* = 6.6, 0.5, H–C(4)); 3.39 (*s*, MeO); 3.36 (*ddd*, *J* = 6.9, 2.7, 0.9, H–C(3)). ¹³C-NMR (75 MHz, CDCl₃): 101.84 (*d*, C(1)); 68.93 (*d*, C(2)); 60.81 (*t*, C(5)); 56.35 (*q*, MeO); 54.32, 53.17 (2*d*, C(3), C(4)); 18.11, 18.08 (2*q*, (Me₂CH)₃Si); 12.48 (*d*, (Me₂CH)₃Si). Anal. calc. for C₁₅H₃₀O₄Si (302.48): C 59.56, H 10.00; found: C 59.64, H 10.01.

Methyl 4-Cyano-4-deoxy-2-O-(triisopropylsilyl)-α-D-lyxopyranoside (17). A cooled soln. (*ca.* 3°) of **16** (4.71 g, 15.88 mmol) in anhyd. Et₂O (58 ml, 0.27*M*) was slowly treated with *ca.* 1*M* soln. of Et₂AlCN in toluene (19 ml, 19 mmol), allowed to warm to r.t., and then heated under reflux for *ca.* 4 h until disappearance of **16**. The mixture was cooled in an ice-bath and treated dropwise with sat. aq. NH₄Cl soln. (*ca.* 20 ml) (*caution*: exothermic reaction!). The mixture was stirred for an additional 2 h, the liquid phase was decanted, and the solid was thoroughly washed with AcOEt (2 × 25 ml). Evaporation of the combined filtrate, washings, and FC (100 g of silica gel; hexane/AcOEt 9:1 → 17:3) gave **17** (4.52 g, 88%). Colourless solid. *R_f* (hexane/AcOEt 17:3) 0.34; *R_f* (hexane/AcOEt 9:1) 0.46. M.p. 78–78.3° (MeOH/H₂O). $[\alpha]_D^{25} = -17.1$ (*c* = 1.01, CHCl₃). IR (CHCl₃): 3562*w*, 3018*w*, 2946*s*, 2869*s*, 2249*w*, 1464*m*, 1389*w*, 1369*w*, 1149*s*, 1132*s*, 1070*s*, 1030*s*, 998*w*, 973*w*, 883*m*. ¹H-NMR (300 MHz, CDCl₃): 4.61 (*d*, *J* = 2.4, H–C(1)); 4.03 (*td*, *J* = 9.6, 3.0, addn. of D₂O → *dd*, *J* = 9.6, 3.0, H–C(3)); 3.98 (*dd*, *J* = 3.0, 2.4, irradiat. at 4.61 → *d*, *J* = 3.0, H–C(2)); 3.87 (*dd*, *J* = 11.1, 4.5, H_{eq}–C(5)); 3.78 (*dd*, *J* = 11.1, 10.2, H_{ax}–C(5)); 3.38 (*s*, MeO), 3.01 (*td*, *J* ≈ 9.6, 4.5, H–C(4)); 2.44 (*d*, *J* = 9.3, exchanged with D₂O, HO–C(3)); 1.08 (*br. s*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 118.28 (*s*, CN); 101.31 (*d*, C(1)); 69.94, 68.41 (2*d*, C(2), C(3)); 59.01 (*t*, C(5)); 55.63 (*q*, MeO); 32.53 (*d*, C(4)); 18.18, 18.10 (2*q*, (Me₂CH)₃Si); 12.65 (*d*, (Me₂CH)₃Si). MALDI-MS: 681.4 ([2*M* + Na]⁺, C₃₂H₆₂N₂NaO₈Si₂⁺; calc. 681.3937). Anal. calc. for C₁₆H₃₁NO₄Si (329.51): C 58.32, H 9.48, N 4.25; found: C 58.18, H 9.59, N 4.22.

Methyl 4-Carbamoyl-4-deoxy-2-O-(triisopropylsilyl)-α-D-lyxopyranoside (18) and Methyl 4-Carbamoyl-4-deoxy-3-O-(triisopropylsilyl)-α-D-lyxopyranoside (19). A cold (0–5°) soln. of **17** (2.01 g, 6.10 mmol) in Me₂CO/H₂O 3:2 (50 ml) was treated with 1*M* aq. K₂CO₃ soln. (12.5 ml, 12.5 mmol) and 30% aq. H₂O₂ (3 ml, 26.4 mmol), warmed to 25°, stirred for *ca.* 16 h (disappearance of **17**), and treated with sat. aq. NaHSO₃ soln. (5 ml). After evaporation, the residue was taken up in AcOEt (200 ml), washed with 20% aq. HCl soln. (40 ml), H₂O (20 ml), and brine (20 ml), and dried (Na₂SO₄). Evaporation gave crude **18/19** *ca.* 1:1 (2.21 g), which was used for the

next step without further purification. Colourless solid. R_f (AcOEt/hexane 3:2) 0.22. IR (CHCl₃): 3525 m , 3494 m , 3406 m , 3360 w , 3194 w , 3007 m , 2946 s , 2868 s , 1684 s , 1559 m , 1464 m , 1407 w , 1386 m , 1366 m , 1148 s , 1107 s , 1061 s , 1014 s , 973 s , 919 w , 883 w , 862 w . ¹H-NMR (300 MHz, CDCl₃; **18/19** *ca.* 1:1): 6.73, 6.30, 6.13, 6.10 (4 br. *s*, slowly exchanged with D₂O, NH₂); 4.68 (*d*, $J = 1.8$, 0.5 H), 4.62 (*d*, $J = 2.1$, 0.5 H) (H–C(1)); 4.40 (*dd*, $J = 9.3$, 3.0, 0.5 H), 4.01 (*td*, $J = 9.9$, 3.6, addn. of D₂O → *dd*, $J = 9.9$, 3.3, 0.5 H) (H–C(3)); 3.91 (br. *q*, $J \approx 1.8$, addn. of D₂O → br. *t*, $J \approx 1.8$, 0.5 H–C(2)); 3.84 (br. *dd*, $J = 12.0$, 5.1, 0.5 H_{eq}–C(5)); 3.80–3.63 (*m*, 0.5 H–C(2), 0.5 H_{eq}–C(5), H_{ax}–C(5)); 3.32, 3.31 (2*s*, MeO); 2.82 (*td*, $J = 10.8$, 5.1, 0.5 H), 2.75 (*td*, $J = 10.5$, 5.4, 0.5 H) (H–C(4)); 2.73 (*d*, $J = 9.3$, exchanged with D₂O, 0.5 HO–C(3)); 2.66 (*d*, $J = 1.8$, exchanged with D₂O, 0.5 HO–C(2)); 1.09–1.01 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃; **18/19** *ca.* 1:1): 174.27, 173.54 (2*s*, C=O); 101.05, 100.84 (2*d*, C(1)); 70.49, 69.58, 68.88, 67.69 (4*d*, C(2), C(3)); 60.21, 59.35 (2*t*, C(5)); 55.11, 55.08 (2*q*, MeO); 46.34, 44.51 (2*d*, C(4)); 18.43, 18.08 (2*q*, (Me₂CH)₃Si); 12.62 (*d*, (Me₂CH)₃Si).

Methyl 4-Carbomyl-4-deoxy- α -D-lyxopyranoside (20). A stirred soln. of **18/19** *ca.* 1:1 (2.21 g, 6.35 mmol) and TBAF·3 H₂O (2.6 g, 8.34 mmol) in dry THF (10 ml) was kept for 3 h at 83°. Evaporation, FC (24 g of silica gel; AcOEt → AcOEt/MeOH 9:1), and recrystallisation in AcOEt/MeOH gave **20** (916 mg, 78% from **17**). Colourless solid. R_f (MeOH/AcOEt 1:9) 0.24. M.p. 128.7–129.8° (MeOH/AcOEt). $[\alpha]_D^{25} = +52.3$ ($c = 0.52$ EtOH). IR (KBr): 3409 s , 3225 s , 3175 s , 3007 m , 2956 s , 2938 s , 2885 m , 1682 s , 1641 s , 1621 s , 1439 s , 1384 s , 1355 s , 1250 s , 1142 s , 1126 s , 1089 s , 1059 s , 1009 s , 964 s , 941 w , 881 w , 846 w . ¹H-NMR (300 MHz, D₂O): 4.65 (*d*, $J = 2.1$, H–C(1)); 3.98 (*dd*, $J = 10.8$, 3.0, irradi. at 2.79 → change, H–C(3)); 3.73 (*dd*, $J = 3.0$, 2.1, H–C(2)); 3.71 (*dd*, $J = 11.1$, 5.4, irradi. at 2.79 → change, H_{eq}–C(5)); 3.62 (*t*, $J \approx 11.1$, irradi. at 2.79 → change, H_{ax}–C(5)); 3.27 (*s*, MeO); 2.79 (*td*, $J \approx 11.1$, 5.4, irradi. at 3.98 → *dd*, $J = 11.1$, 5.4, H–C(4)). ¹³C-NMR (75 MHz, D₂O): 175.54 (*s*, C=O); 101.05 (*d*, C(1)); 67.96, 66.07 (2*d*, C(2), C(3)); 59.63 (*t*, C(5)); 54.74 (*q*, MeO); 44.86 (*d*, C(4)). Anal. calc. for C₁₀H₁₇O₅N (231.25): C 51.94, H 7.41; N 6.06; found: C 52.07, H 7.27, N 6.02.

Isopropylidenation of 20. A soln. of **20** (592 mg, 3.1 mmol) in anh. Me₂CO (20 ml) was treated with powdered molecular sieves (4 Å; 670 mg) and Amberlyst-15 (H⁺ form, 215 mg), stirred at 24° for 4 h, and filtered through a short plug of Celite (washing with 15 ml of Me₂CO). Evaporation and FC (*ca.* 15 g of silica gel; 300 ml of hexane/AcOEt 4:1) gave **21** (582 mg, 81%), and **22** (85 mg, 12%, containing traces of **21**).

Methyl 4-Carbamoyl-4-deoxy-2,3-O-isopropylidene- α -D-lyxopyranoside (21). Colourless solid. R_f (hexane/AcOEt 2:3) 0.21. M.p. 159–159.8° (CH₂Cl₂/hexane). $[\alpha]_D^{25} = +21.0$ ($c = 1.01$, CHCl₃). IR (*ca.* 3%, CHCl₃): 3502 m , 3386 m , 3007 m , 2937 m , 2838 m , 1682 s , 1589 s , 1466 w , 1385 s , 1370 s , 1248 w , 1142 s , 1093 s , 1057 s , 1006 m , 908 w , 953 w , 851 m . ¹H-NMR (300 MHz, CDCl₃): 6.28, 5.36 (2 br. *s*, exchanged with D₂O, NH₂); 4.88 (br. *s*, $J < 1.5$, H–C(1)); 4.36 (*dd*, $J = 9.3$, 5.4, H–C(3)); 4.02 (*dd*, $J = 5.4$, 1.8, H–C(2)); 3.84 (*dd*, $J = 12.3$, 4.8, H_{eq}–C(5)); 3.72 (*dd*, $J = 12.3$, 10.8, H_{ax}–C(5)); 3.39 (*s*, MeO); 2.66 (*ddd*, $J \approx 10.5$, 9.3, 4.8, H–C(4)); 1.58, 1.37 (2*s*, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 173.84 (*s*, C=O); 109.68 (*s*, Me₂C); 98.54 (*d*, C(1)); 73.52, 72.94 (2*d*, C(2), C(3)); 57.11 (*t*, C(5)); 55.14 (*q*, MeO); 44.46 (*d*, C(4)); 28.42, 26.30 (2*q*, Me₂C). Anal. calc. for C₁₀H₁₇O₅N (231.245): C 51.94, H 7.41, N 6.06; found: C 52.07, H 7.27, N 6.02.

Methyl 4-Carbamoyl-4-deoxy-3-O,4'-N-isopropylidene- α -D-lyxopyranoside (22). Colourless oil. R_f (hexane/AcOEt 2:3) 0.21. $[\alpha]_D^{25} = +43.0$ ($c = 0.7$, CHCl₃). IR (CHCl₃): 3599 w , 3500 w , 3396 w , 3017 m , 2936 w , 1667 s , 1591 w , 1426 m , 1389 w , 1373 w , 1215 s , 1161 m , 1125 m , 1091 w , 1055 s , 1017 m , 999 m . ¹H-NMR (300 MHz, CDCl₃): 6.70 (br. *s*, slowly exchanged with D₂O, NH₂); 4.74 (*d*, $J = 1.5$, H–C(1)); 4.02 (*dd*, $J = 11.7$, 4.8, H_{eq}–C(5)); 4.01 (*dd*, $J = 10.8$, 2.7, H–C(3)); 3.94 (*td*, $J \approx 3.0$, 1.5, addn. of D₂O → *dd*, $J \approx 3.0$, 1.5, H–C(2)); 3.62 (*t*, $J \approx 11.4$, H_{ax}–C(5)); 3.37 (*s*, MeO); 2.66 (*td*, $J \approx 11.1$, 4.8, H–C(4)); 2.41 (*d*, $J = 3.0$, exchanged with D₂O, HO–C(2)); 1.49, 1.48 (2*s*, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 168.84 (*s*, C=O); 100.86 (*d*, C(1)); 85.90 (*s*, Me₂C); 68.25, 67.61 (2*d*, C(2), C(3)); 57.76 (*t*, C(5)); 55.16 (*q*, MeO); 37.61 (*d*, C(4)); 31.21, 27.78 (2*q*, Me₂C). HR-EI-MS: 216.0873 ([*M*–Me]⁺, C₉H₁₄NO₄⁺; calc. 216.0877).

Methyl 4-(Aminothiobonyl)-4-deoxy-2,3-O-isopropylidene- α -D-lyxopyranoside (23). A soln. of **21** (30 mg, 0.129 mmol) in dry toluene (1 ml) was treated with Lawesson's reagent (35.4 mg, 0.88 mmol) at 23°, heated to 70°, and stirred for 15 min (disappearance of **21**). Evaporation and FC (*ca.* 2 g of silica gel; hexane/AcOEt 7:3) gave **23** (27 mg, 84%). Yellowish solid. R_f (hexane/AcOEt 7:3) 0.22. M.p. 139–139.5° (CH₂Cl₂/hexane). $[\alpha]_D^{25} = -8.2$ ($c = 0.96$, CHCl₃). IR (*ca.* 1%, CHCl₃): 3468 w , 3337 w , 2992 m , 2937 w , 1601 m , 1400 m , 1385 m , 1370 w , 1246 w , 1161 w , 1140 m , 1092 s , 1055 s , 1005 m , 954 w , 894 w , 856 m . ¹H-NMR (300 MHz, CDCl₃): 7.78, 7.59 (2 br. *s*, exchanged slowly with D₂O, NH₂); 4.88 (br. *s*, $J < 1$, H–C(1)); 4.39 (*dd*, $J = 8.7$, 5.4, H–C(3)); 4.03 (*dd*, $J = 5.4$, 0.5, H–C(2)); 3.88 (*dd*, $J = 12.1$, 4.8, H_{eq}–C(5)); 3.80 (*dd*, $J = 12.1$, 9.6, H_{ax}–C(5)); 3.39 (*s*, MeO); 2.83 (*ddd*, $J \approx 9.6$, 8.7, 4.8, H–C(4)); 1.57, 1.36 (2*s*, Me₂C). ¹³C-NMR (75 MHz, CDCl₃): 207.82 (*s*, C=S); 109.62 (*s*, Me₂C); 98.45 (*d*, C(1)); 74.92, 73.67 (2*d*, C(2), C(3)); 59.33 (*t*, C(5)); 55.22 (*q*, MeO); 50.06 (*d*, C(4)); 28.53, 26.29 (2*q*, Me₂C). HR-MALDI-MS: 232.0644 ([*M*–Me]⁺, C₉H₁₄NO₄S⁺; calc. 232.0628). Anal. calc. for C₁₀H₁₇NO₄S (249.30): C 48.57, H 6.93, N 5.66; found: C 49.11, H 7.04, N 5.54.

Transformation of 23 to 15. At -15° , a soln. of **23** (10 mg, 0.0405 mmol) in THF (1 ml) was treated with aminoacetaldehyde dimethyl acetal (87 μ l, 0.81 mmol) and then with $\text{Hg}(\text{OAc})_2$ (13 mg, 0.41 mmol). The mixture was stirred for 35 min (complete consumption of **23**), and filtered through a short plug of *Celite* (washed with AcOEt). The combined org. layers (ca. 15 ml) were washed with sat. aq. NaHCO_3 soln., dried (Na_2SO_4), and evaporated. FC (silica gel, hexane/ AcOEt 4:1) gave **15** (7 mg, 81%), which could not be distinguished from a sample of **15** prepared from **8**.

Methyl 2,3-Di-O-acetyl-4-carbamoyl-4-deoxy- α -D-lyxopyranoside (24). A mixture of **20** (83 mg, 0.43 mmol) in dry pyridine (1 ml) was treated with Ac_2O (0.3 ml, 0.88 mmol) and DMAP (2 mg, 0.016 mmol), stirred for 16 h at 23.5° , diluted with AcOEt (25 ml), washed with H_2O (5 ml) and 5% aq. HCl (5 ml), dried (Na_2SO_4), and filtered through a short column (ca. 1 g of silica gel). Evaporation of the filtrate and crystallisation from (CH_2Cl_2 /hexane) gave **24** (92 mg, 74%). Colourless solid. R_f (hexane/ AcOEt 3:2) 0.70. M.p. $192-193.3^{\circ}$ (CH_2Cl_2 /hexane). $[\alpha]_D^{25} = +13.3$ ($c = 0.35$, CHCl_3). IR (ca. 1%, CHCl_3): 3408w, 3015w, 2876w, 2839w, 1749s, 1692m, 1592w, 1374m, 1255w, 1134m, 1076m, 1048m, 1024s, 973w, 904w, 877m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 5.63 (br. s, exchanged with D_2O , NH); 5.49 (dd, $J = 11.1, 3.3$, H-C(3)); 5.43 (br. s, exchanged with D_2O , NH); 5.21 (dd, $J = 3.3, 1.8$, H-C(2)); 4.67 (d, $J = 1.8$, H-C(1)); 3.95 (t, $J \approx 11.4$, $\text{H}_{\text{ax}}\text{-C(5)}$); 3.86 (dd, $J = 11.4, 5.1$, $\text{H}_{\text{eq}}\text{-C(5)}$); 3.39 (s, MeO); 3.00 (td, $J \approx 11.1, 4.8$, H-C(4)); 2.14, 2.01 (2s, 2 AcO). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 171.66 (s, $\text{H}_2\text{NC=O}$); 169.99, 169.54 (2s, 2 OC=O); 98.92 (d, C(1)); 67.76 (d, C(2)), C(3)); 60.23 (t, C(5)); 55.26 (q, MeO); 44.55 (d, C(4)); 20.94, 20.82 (2q, 2 Me). HR-MALDI-MS: 298.0893 ($[M + \text{Na}]^+$, $\text{C}_{11}\text{H}_{17}\text{NNaO}_7$; calc. 298.0897). Anal. calc. for $\text{C}_{11}\text{H}_{17}\text{NO}_7$ (275.26): C 48.00, H 6.22, N 5.09; found: C 48.17, H 6.20, N 5.02.

Methyl 2,3-Di-O-acetyl-4-(aminothiocarbonyl)-4-deoxy- α -D-lyxopyranoside (25). A stirred mixture of **24** (102 mg, 0.37 mmol) and Lawesson's reagent (95 mg, 0.225 mmol) in dry toluene (2 ml) was kept at 98° for 20 min (disappearance of **24**). Evaporation and FC (ca. 3 g of silica gel; hexane/ AcOEt 7:3 $\rightarrow$ 2:3) gave **25** (82 mg, 76%). Colourless solid. R_f (hexane/ AcOEt 3:2) 0.48. M.p. $195-197^{\circ}$ (CH_2Cl_2 /hexane). $[\alpha]_D^{25} = +3.6$ ($c = 1.08$, CHCl_3). IR (ca. 1%, CHCl_3): 3488w, 3373w, 3197w, 3017w, 2839w, 1748s, 1603m, 1426w, 1374m, 1320w, 1294w, 1240s, 1133m, 1075s, 1022s, 977w, 909w, 861m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 7.61 (br. s, exchanged with D_2O , NH); 7.14 (br. s, exchanged with D_2O , NH); 5.58 (dd, $J = 11.1, 3.3$, H-C(3)); 5.22 (dd, $J = 3.2, 1.8$, H-C(2)); 4.68 (d, $J = 1.8$, H-C(1)); 4.03 (t, $J \approx 11.1$, $\text{H}_{\text{ax}}\text{-C(5)}$); 3.88 (dd, $J = 11.1, 4.8$, $\text{H}_{\text{eq}}\text{-C(5)}$); 3.40 (s, MeO); 2.83 (td, $J \approx 11.1, 4.8$, H-C(4)); 2.14, 1.98 (2s, 2 AcO). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 204.76 (s, C=S); 169.79, 169.48 (2s, 2 C=O); 99.05 (d, C(1)); 69.85, 68.02 (2d, C(2), C(3)); 62.94 (t, C(5)); 55.47 (q, MeO); 50.39 (d, C(4)); 21.12, 20.91 (2q, 2 Me). Anal. calc. for $\text{C}_{11}\text{H}_{17}\text{NO}_6\text{S}$ (291.32): C 45.35, H 5.88, N 4.78; found: C 45.17, H 5.66, N 4.78.

Methyl 2,3-Di-O-acetyl-4-cyano-4-deoxy- α -D-lyxopyranoside (26). A soln. of **25** (52 mg, 0.178 mmol) in THF (2 ml) was cooled to 0° , treated with $\text{NH}_2\text{CH}_2\text{CH}(\text{OMe})_2$ (100 μ l, 0.93 mmol) and $\text{Hg}(\text{OAc})_2$ (81 mg, 0.254 μ mol), stirred for 5 h (consumption of **25**), diluted with AcOEt (25 ml), and filtered through a short plug of *Celite* (AcOEt). The filtrate (ca. 25 ml) was washed with H_2O (5 ml) and brine (25 ml), dried (Na_2SO_4), and evaporated. FC (ca. 2 g of silica gel; hexane/ AcOEt 7:3) gave **26** (33 mg, 77%). Colourless solid. R_f (hexane/ AcOEt 7:3) 0.38. M.p. $121-122^{\circ}$. $[\alpha]_D^{25} = +9.4$ ($c = 0.9$, CHCl_3). IR (CHCl_3): 3038w, 2961w, 2928s, 2841w, 2250w, 1751s, 1602w, 1463w, 1375m, 1295w, 1261m, 1156m, 1134s, 1077s, 1026m, 978w, 920w, 903w, 875w, 850m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 5.40 (dd, $J = 11.4, 3.0$, H-C(3)); 5.19 (dd, $J = 3.0, 2.1$, H-C(2)); 4.67 (d, $J = 2.1$, H-C(1)); 3.98 (dd, $J = 11.4, 6.3$, $\text{H}_{\text{eq}}\text{-C(5)}$); 3.94 (dd, $J = 11.4, 10.5$, $\text{H}_{\text{ax}}\text{-C(5)}$); 3.41 (s, MeO); 3.26 (ddd, $J = 11.4, 10.5, 6.0$, H-C(4)); 2.14, 2.08 (2s, 2 Me). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 169.53, 169.09 (2s, 2 C=O); 116.44 (s, CN); 98.81 (s, C(1)); 67.02, 66.64 (2d, C(2), C(3)); 58.78 (t, C(5)); 55.71 (q, MeO); 29.22 (d, C(4)); 20.95, 20.77 (2q, 2 Me). Anal. calc. for $\text{C}_{11}\text{H}_{15}\text{NO}_6$ (257.2399): C 51.36, H 5.88, N 5.44; found: C 51.48, H 5.76, N 5.43.

Methyl 4-Deoxy-4-(1H-imidazol-2-yl)-2-O-(triisopropylsilyl)- α -D-lyxopyranoside (27). A cold (3°) soln. of **17** (4.3 g, 13.06 mmol) in anh. toluene (40 mmol) was treated with a premixed soln. of Me_3Al and $\text{NH}_2\text{CH}_2\text{CH}(\text{OMe})_2$ in toluene (24 ml, 21.6 mmol, ca. 0.9M), warmed slowly to 23° , and kept for 26 h at 90° . The mixture was allowed to cool and treated carefully with a sat. aq. NH_4Cl soln. (25 ml) to allow precipitation of the aluminium salts. After filtration and washing with AcOEt (350 ml), the combined org. layers were washed with H_2O (2×40 ml) and brine, dried (Na_2SO_4), and evaporated. FC (ca. 105 g, hexane/ AcOEt 9:1 $\rightarrow$ 7:3) gave **17** (620 mg, 14%) and **27** (2.54 g, 53%). Yellow solid. R_f (AcOEt) 0.34. M.p. $113.9-114.8^{\circ}$ (hexane). $[\alpha]_D^{25} = +3.0$ ($c = 1.01$, CHCl_3). UV (EtOH, qualitative, λ_{max}): 210 nm. IR (1.5%, CHCl_3): 3551m, 3423m, 2946s, 2869s, 1541m, 1464m, 1437m, 1371m, 1268m, 1132s, 1111s, 1086m, 1070s, 1020s, 998m, 967m, 910m, 884m, 838w. $^1\text{H-NMR}$ (400 MHz, CDCl_3 ; assignment based on a DQFCOSY and a HSQC spectrum): 9.98 (br. s, NH, exchanged with D_2O); 6.97 (br. s, H-C(4'), H-C(5')); 4.68 (d, $J = 2.2$, H-C(1)); 4.16 (dd, $J = 11.7, 5.1$, $\text{H}_{\text{eq}}\text{-C(5)}$); 4.05 (br. s, addn. of $\text{D}_2\text{O} \rightarrow$ dd, $J = 9.9, 3.0$, H-C(3)); 3.96 (t, $J \approx 2.5$, H-C(2)); 3.85 (dd, $J = 11.7$,

10.5, $H_{ax}-C(5a)$); 3.37 (*s*, MeO); 3.29 (*td*, $J \approx 10.5, 4.8$, $H-C(4)$); 2.78 (*br. s*, exchanged with D_2O , $HO-C(3)$); 1.14–1.04 (*m*, $(Me_2CH)_3Si$). ^{13}C -NMR (100 MHz, $CDCl_3$): 146.73 (*s*, $C(2')$); 127.83 (*br. d*, $C(4')$); 115.19 (*br. d*, $C(5')$); 101.34 (*d*, $C(1)$); 70.56 (*d*, $C(2)$); 69.82 (*d*, $C(3)$); 60.33 (*t*, $C(5)$); 55.04 (*q*, MeO); 38.02 (*d*, $C(4)$); 17.94 (*q*, $(Me_2CH)_3Si$); 12.57 (*d*, $(Me_2CH)_3Si$). HR-MALDI-MS: 393.2172 ($[M+Na]^+$, $C_{18}H_{34}N_2NaO_4Si^+$; calc. 393.2180). Anal. calc. for $C_{18}H_{34}N_2O_4Si$ (370.23): C 58.34, H 9.25, N 7.56; found: C 58.26, H 9.18, N 7.58.

(5*R*,6*S*,7*R*,8*R*)-5,6,7,8-Tetrahydro-8-(hydroxymethyl)imidazo[1,2-*a*]pyridine-5,6,7-triol (**4/28**) and 4-Deoxy-4-(1*H*-imidazol-2-yl)- α/β -D-lyxopyranoside (**29/30**). A stirred soln. of **27** (365 mg, 0.78 mmol) in 80% aq. AcOH (6.8 ml) was treated with 20% aq. HCl (1.15 ml, *ca.* 2.3 mmol) was kept at 113°. After stirring for 2.5 h, it was cooled to 24°. Evaporation and FC (9 g of silica gel; AcOEt/MeOH/ H_2O 13:6:1) gave pure **4/28/29/30** (182 mg, 95%), which was filtered through a short plug of Amberlite-CG 120 (H^+ form, 2% NH_4OH) and lyophilised. Hygroscopic solid. R_f (AcOEt/MeOH/ H_2O 13:6:1) 0.52. R_f (AcOEt/MeOH/ H_2O 7:2:1) 0.65. $[\alpha]_D^{25} = +0.4$ (*c* = 1.55, EtOH). IR (KBr): 3460s, 2925w, 2855w, 1631w, 1488w, 1452w, 1263w, 1172w, 1092w, 1041w, 928w, 833w. 1H -NMR (300 MHz, CD_3OD ; **4/28/29/30** *ca.* 60:8:14:18): 7.08 (*br. s*, 0.68 H, $H-C(2)$ of **4/28**); 6.90–6.87 (3 *br. s*, 1.68 H, $H-C(3)$ of **4/28**, $H-C(4')$ and $H-C(5')$ of **29/30**); 5.47 (*d*, J = 3.6, 0.8 H), 5.32 (*d*, J = 7.2, 0.60 H) ($H-C(5)$ of **4/28**); 5.06 (*d*, J = 4.8, 0.14 H), 4.67 (*br. s*, 0.18 H) ($H-C(1)$ of **29/30**); 4.40–3.15 (*m*) ($H-C(6)$, $H-C(7)$, and $CH_2-C(8)$ of **4**, and $H-C(2)$, $H-C(3)$, $H-C(4)$, $H-C(5_{ax})$, and $H-C(5_{eq})$ of **29/30**); 4.35 (*dd*, J = 3.6, 1.5, 0.60 H, $H-C(7)$ of **4**); 4.20 (*dd*, J = 10.8, 4.2, 0.60 H, $CH_2-C(8)$ of **4**); 3.84 (*dd*, J = 10.8, 9.3, 0.60 H, $CH_2-C(8)$ of **4**); 3.73 (*dd*, J = 7.2, 1.5, 0.60 H, $H-C(6)$ of **4**); 3.35–3.15 (*m*, 0.32 H, $H-C(4)$ of **29/30**); 3.05–2.98 (*m*), 3.01 (*br. ddd*, J = 8.4, 4.2, 3.6, 0.6 H) ($H-C(8)$ of **4/28**). ^{13}C -NMR (75 MHz, CD_3OD , **4/28/29/30** *ca.* 60:8:14:18): 147.39 (*s*, 0.18 C), 146.91 (*s*, 0.14 C), 145.70 (*s*, 0.6 C), 144.36 (*s*, 0.08 C), (C(8a) of **4/28** and C(2') of **29/30**); 128.29 (*d*, 0.08 C), 127.42 (*d*, 0.6 C) (C(2) of **4/28**); 122.33 (*d*, 0.28 C), 121.82 (*d*, 0.36 C) (C(4') and C(5') of **29/30**); 119.68 (*d*, 0.08 C), 118.23 (*d*, 0.6 C) (C(3) of **4/28**); 96.86 (*d*, 0.14 C), 96.04 (*d*, 0.18 C) (C(1) of **29/30**); 81.58 (*d*, 0.6 C), 79.24 (*d*, 0.08 C) (C(5) of **4/28**); 75.14 (*d*, 0.6 C, C(6) of **4**); 71.72 (*d*, 0.08 C), 71.30 (*d*, 0.18 C), 70.85 (*d*, 0.14 C), 69.42 (*d*, 0.18 C), 69.30 (*d*, 0.14 C), 69.15 (*d*, 0.08 C) (C(6) and C(7) of **28**, C(2) and C(3) of **29/30**); 70.04 (*d*, 0.6 C, C(7) of **4**); 61.44 (*t*, 0.32 C), 61.43 (*t*, 0.6 C), 60.99 (*t*, 0.08 C) ($CH_2-C(8)$ of **4/28** and C(5) of **29/30**); 42.81 (*d*, 0.6 C), 42.31 (*d*, 0.14 C), 40.75 (*d*, 0.08 C), 39.97 (*d*, 0.18 C) (C(8) of **4/28** and C(4) of **29/30**). HR-MALDI-MS of the HCl salts: 201.0871 ($[M+H-HCl]^+$, $C_8H_{13}N_2O_4^+$; calc. 201.0870).

2-Deoxy-2-(1*H*-imidazol-2-yl)-D-arabinitol (**31**). A soln. of **4/28–30** (41 mg, 0.203 mmol) in dry MeOH (1 ml) was treated with AcOH (100 μ l) and $NaCNBH_3$ (53 mg, 0.84 mmol), stirred for 60 h at 26°, and evaporated. FC (*ca.* 6 g of silica gel; AcOEt $\rightarrow$ AcOEt/MeOH 9:1 $\rightarrow$ AcOEt/MeOH/ NH_4OH 7:2:1) gave **31** (34 mg, 90%). Colourless syrup. R_f (AcOEt/MeOH/ H_2O 7:2:1) 0.45. $[\alpha]_D^{25} = -15.1$ (*c* = 0.1, EtOH). 1H -NMR (300 MHz, CD_3OD): 6.91 (*br. s*, $H-C(4')$, $H-C(5')$); 3.90 (*dd*, J = 10.8, 7.8, irradi. at 3.44 $\rightarrow$ change, $H_a-C(5)$); 3.88 (*dd*, J = 9.0, 2.7, irradi. at 3.44 $\rightarrow$ change, irradi. at 3.11 $\rightarrow$ change, $H-C(3)$); 3.80 (*dd*, J = 10.8, 6.6, irradi. at 3.44 $\rightarrow$ change, $H_b-C(5)$); 3.67 (*dd*, J = 11.4, 3.6, irradi. at 3.11 $\rightarrow$ J = 10.8, $H_b-C(1)$); 3.51 (*dd*, J = 11.4, 6.3, irradi. at 3.11 $\rightarrow$ J = 10.8, $H_a-C(1)$); 3.44 (*ddd*, J = 7.8, 6.6, 2.7, $H-C(4)$); 3.11 (*ddd*, J = 9.6, 6.3, 3.6, irradi. at 3.51 $\rightarrow$ change, $H-C(2)$). ^{13}C -NMR (75 MHz, CD_3OD): 147.94 (*s*, $C(2')$); 122.16 (*br. s*, $C(4')$, $C(5')$); 73.82, 71.94 (2*d*, C(3), C(4)); 65.21, 63.66 (2*t*, C(1), C(5)); 45.0 (*d*, C(2)). HR-MALDI-MS: 242.2839 ($[M+K]^+$, $C_8H_{14}KN_2O_4^+$; calc. 242.0669); 225.0846 ($[M+Na]^+$, $C_8H_{14}N_2NaO_4^+$; calc. 225.0840); 203.1026 ($[M+H]^+$, $C_8H_{15}N_2O_4^+$; calc. 203.1026).

Silylation of **4/28–30**. A soln. of **4/28–30** (470 mg, 1.99 mmol) in dry pyridine (8 ml) at 2° was treated with 2,6-lutidine (1 ml, 8.41 mmol) and Et_3SiCl (3.0 ml, 17.88 mmol). The mixture was stirred for 24 h at 27°, diluted with AcOEt (200 ml), washed with H_2O (5×20 ml) and brine (5 ml), dried (Na_2SO_4), and evaporated. FC (*ca.* 12 g of silica gel; *ca.* 50 ml of AcOEt/hexane 1:4) gave **32** (212 mg, 16%), **33** (230 mg, *ca.* 90% pure, 22%) and **34** (85 mg, 8%).

(5*R*,6*S*,7*R*,8*R*)-5,6,7,8-Tetrahydro-5,6,7-tris(triethylsilyloxy)-8-[(triethylsilyloxy)methyl]imidazo[1,2-*a*]pyridine (**32**). Colourless oil. R_f (hexane/AcOEt 7:3) 0.81. $[\alpha]_D^{25} = +0.5$ (*c* = 2.9, $CHCl_3$). IR ($CHCl_3$): 2958s, 2913s, 2878s, 1525w, 1490w, 1458w, 1414w, 1381w, 1255m, 1156m, 1139m, 1093s, 1008s, 962w, 885w, 862w. 1H -NMR (300 MHz, CD_3OD): 7.00 (*d*, J = 1.5, $H-C(2)$); 6.90 (*d*, J = 1.2, $H-C(3)$); 5.50 (*d*, J = 5.4, $H-C(5)$); 4.49 (*dd*, J = 4.2, 1.5, $H-C(7)$); 4.09 (*dd*, J = 9.9, 5.7, $CH_a-C(8)$); 3.93 (*dd*, J = 9.9, 7.2, $CH_b-C(8)$); 3.87 (*dd*, J = 5.7, 1.5, $H-C(6)$); 3.20 (*ddd*, J = 7.2, 5.7, 4.2, $H-C(8)$); 1.03–0.61 (*m*, 4 $(MeCH_2)_3Si$). 1H -NMR (300 MHz, $CDCl_3$): 6.94 (*d*, J = 1.5, $H-C(2)$); 6.91 (*d*, J = 1.2, $H-C(3)$); 5.46 (*d*, J = 6.9, $H-C(5)$); 4.41 (*dd*, J = 3.0, 1.5, $H-C(7)$); 4.27 (*dd*, J = 9.9, 5.1, $CH_a-C(8)$); 3.93 (*t*, $J \approx 9.6$, $CH_b-C(8)$); 3.87 (*dd*, J = 6.6, 1.5, $H-C(6)$); 2.93 (*br. ddd*, $J \approx 9.0, 5.1, 3.0$, $H-C(8)$); 1.03–0.56 (*m*, 4 $(MeCH_2)_3Si$). ^{13}C -NMR (75 MHz, CD_3OD , assignment based on a HSQC spectrum): 146.11 (*s*, C(8a)); 128.89 (*d*, C(2)); 118.30 (*d*, C(3)); 82.69 (*d*, C(5)); 77.82 (*d*,

C(6)); 70.86 (*d*, C(7)); 61.55 (*t*, CH₂–C(8)); 45.68 (*d*, C(8)); 7.60, 7.56, 7.42, 7.39 (4*q*, 4 (MeCH₂)₃Si); 6.28, 5.59 (2*t*, 4 (MeCH₂)₃Si). HR-MALDI-MS: 657.4336 ([*M* + H]⁺, C₃₂H₆₉N₂O₄Si₄⁺; calc. 657.4329).

(5*R*,6*S*,7*R*,8*R*)-5,6,7,8-Tetrahydro-5,6-bis(triethylsilyloxy)-8-[(triethylsilyloxy)methyl]imidazo[1,2-*a*]pyridin-7-ol (**33**). Colourless oil. *R*_f (hexane/AcOEt 7:3) 0.61. IR (CHCl₃): 3411*w*, 2959*s*, 2813*s*, 2878*s*, 1525*w*, 1458*m*, 1414*m*, 1338*w*, 1251*m*, 1128*s*, 1090*s*, 1055*s*, 885*m*, 861*w*. ¹H-NMR (300 MHz, CDCl₃; *ca.* 90% pure): 7.00 (*d*, *J* = 1.5, H–C(2)); 6.87 (*d*, *J* = 1.5, H–C(3)); 5.46 (*d*, *J* = 4.5, H–C(5)); 4.50 (*ddd*, *J* = 6.3, 4.2, 2.1, irradi. at 3.36 → change, irradi. at 4.19 → *dd*, *J* = 6.3, 2.1, addn. of D₂O → *dd*, *J* = 6.3, 2.1, H–C(7)); 4.30–4.28 (*m*, irradi. at 3.36 → *s*, CH₂–C(8)); 4.19 (*d*, *J* = 3.9, HO–C(7), exchanged with D₂O); 4.01 (*dd*, *J* = 4.8, 2.1, irradi. at 5.46 → *d*, *J* = 2.1, H–C(6)); 3.36 (*ddd*, *J* = 8.4, 6.9, 5.4, irradi. at 4.50 → *br. dd*, *J* = 7.8, 7.2, H–C(8)); 1.00–0.94 (*m*, 3 (MeCH₂)₃Si); 0.71–0.66 (*m*, 3 (MeCH₂)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 143.17 (*s*, C(8a)); 128.99 (*d*, C(2)); 117.15 (*d*, C(3)); 81.16 (*d*, C(5)); 76.31 (*d*, C(6)); 68.76 (*d*, C(7)); 64.10 (*t*, CH₂–C(8)); 40.35 (*d*, C(8)); 6.99, 6.93, 6.88 (3*q*, 3 (MeCH₂)₃Si); 5.19, 5.17, 4.46 (3*t*, 3 (MeCH₂)₃Si). HR-MALDI-MS: 565.3283 ([*M* + Na]⁺, C₂₆H₅₄O₅N₂NaSi₃⁺; calc. 565.3284).

(5*S*,6*S*,7*R*,8*R*)-5,6,7,8-Tetrahydro-5,6-bis(triethylsilyloxy)-8-[(triethylsilyloxy)methyl]imidazo[1,2-*a*]pyridin-7-ol (**34**). Colourless solid. *R*_f (hexane/AcOEt 7:3) 0.33. [*α*]_D²⁵ = –17.0 (*c* = 0.65, CHCl₃). IR (CHCl₃): 3506*w*, 2958*s*, 2913*s*, 2878*s*, 1488*m*, 1458*m*, 1378*w*, 1263*m*, 1143*s*, 1119*s*, 1103*s*, 1078*s*, 1007*s*, 976*s*, 956*m*, 864*m*. ¹H-NMR (300 MHz, CDCl₃): 7.01 (*d*, *J* = 1.2, H–C(2)); 6.87 (*d*, *J* = 1.5, H–C(3)); 5.60 (*dd*, *J* = 3.9, 1.8, H–C(5)); 4.46 (*dd*, *J* = 9.6, 4.5, CH₂–C(8)); 4.37 (*m*, addn. of D₂O → *dt*, *J* ≈ 3.9, 2.1, H–C(7)); 4.14 (*dd*, *J* = 10.6, 9.6, CH₂–C(8)); 4.19 (*d*, *J* = 7.2, HO–C(7)); 3.99 (*dd*, *J* = 3.3, 2.4, H–C(6)); 2.93 (*dt*, *J* = 10.8, 4.2, H–C(8)); 1.04–0.94 (*m*, 3 (MeCH₂)₃Si); 0.73–0.64 (*m*, 3 (MeCH₂)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 142.64 (*s*, C(8a)); 129.38 (*d*, C(2)); 117.42 (*d*, C(3)); 80.38 (*d*, C(5)); 70.70, 69.35 (2*d*, C(6), C(7)); 59.32 (*t*, CH₂–C(8)); 42.95 (*d*, C(8)); 6.99, 6.87, 6.70 (3*q*, 3 (MeCH₂)₃Si); 5.08, 4.62 (2*t*, 3 (MeCH₂)₃Si). HR-MALDI-MS: 543.3469 ([*M* + H]⁺, C₂₆H₅₅N₂O₄Si₃⁺; calc. 565.3464).

Methyl 4-Cyano-4-deoxy-3-O-[(trifluoromethyl)sulfonyl]-2-O-(triisopropylsilyl)-α-D-lyxopyranoside (**36**). At –15°, a soln. of **17** (409 mg, 1.24 mmol) in pyridine (2 ml) was treated dropwise with Tf₂O (307 μl, 1.86 mmol). The mixture was stirred for 7 h (disappearance of **17**), diluted with CH₂Cl₂ (30 ml), washed with 10% aq. HCl soln. (5 ml), H₂O (5 ml) and brine (5 ml), and dried (Na₂SO₄). Evaporation and FC (20 g of silica gel; AcOEt/hexane 1:19 → 3:17) gave **36** (548 mg, 99%). Colourless oil. *R*_f (hexane/AcOEt 17:3) 0.46. [*α*]_D²⁵ = –28.2 (*c* = 0.54, CHCl₃). IR (CHCl₃): 2946*m*, 2893*w*, 2869*m*, 2254*w*, 1464*m*, 1421*s*, 1370*w*, 1339*m*, 1168*s*, 1144*s*, 1067*s*, 1041*m*, 1013*w*, 963*s*, 909*m*, 882*m*, 858*s*. ¹H-NMR (300 MHz, CDCl₃): 5.17 (*dd*, *J* ≈ 11, 2.4, H–C(3)); 4.65 (*d*, *J* = 1.8, H–C(1)); 4.29 (*t*, *J* ≈ 2.4, H–C(2)); 4.0 (*dd*, *J* = 11.4, 5.1, H_{eq}–C(5)); 3.85 (*t*, *J* ≈ 11.1, H_{ax}–C(5)); 3.57 (*td*, *J* ≈ 11.1, 5.1, H–C(4)); 3.39 (*s*, MeO); 1.29–1.06 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 118.38 (*q*, *J*(C,F) = 317, CF₃); 115.32 (*s*, C≡N); 101.27 (*d*, C(1)); 82.97 (*d*, C(3)); 69.04 (*d*, C(2)); 59.13 (*t*, C(5)); 55.56 (*q*, MeO); 29.18 (*d*, C(4)); 17.92, 17.89 (2*q*, (Me₂CH)₃Si); 12.58 (*d*, (Me₂CH)₃Si).

Methyl 4-Cyano-3,4-dideoxy-2-O-(triisopropylsilyl)-β-L-glycero-pent-3-enopyranoside (**38**). At 2°, a soln. of **36** (325 mg, 0.704 mmol) in dry DMF (2 ml) was treated slowly with CsOAc (157 mg, 0.82 mmol), stirred for 3 h (disappearance of **36**), diluted with AcOEt (25 ml), washed with H₂O (2 × 10 ml) and brine (10 ml), and dried (Na₂SO₄). Evaporation and FC (*ca.* 6 g of silica gel; AcOEt/hexane 3:97) gave **38** (198 mg, 90%). Colourless oil. *R*_f (AcOEt/hexane 1:9) 0.51. [*α*]_D²⁵ = +175.5 (*c* = 0.78, CHCl₃). IR (CHCl₃): 3026*w*, 2946*s*, 2868*s*, 2226*w*, 1464*m*, 1412*w*, 1391*w*, 1371*w*, 1216*s*, 1152*s*, 1102*s*, 1050*s*, 918*w*, 882*m*. ¹H-NMR (300 MHz, CDCl₃): 6.54 (*ddd*, *J* ≈ 3.6, 2.1, 0.6, H–C(3)); 4.62 (*br. d*, *J* = 3.0, H–C(1)); 4.21 (*dt*, *J* ≈ 16.2, 2.2, H–C(5)); 4.20 (*dt*, *J* ≈ 16.2, 2.2, H'–C(5)); 4.08 (*ddt*, *J* ≈ 3.6, 3.0, 2.2, H–C(2)); 3.47 (*s*, MeO); 1.15–1.03 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 141.37 (*d*, C(3)); 115.75 (*s*, C≡N); 113.73 (*s*, C(4)); 102.08 (*d*, C(1)); 65.12 (*d*, C(2)); 60.21 (*t*, C(5)); 56.44 (*q*, MeO); 18.10, 18.07 (2*q*, (Me₂CH)₃Si); 12.40 (*d*, (Me₂CH)₃Si). Anal. calc. for C₁₆H₂₉NO₃Si (311.49): C 61.69, H 9.38, N 4.50; found: C 61.63, H 9.43, N 4.69.

Methyl 4-Cyano-4-deoxy-3-O-(methylsulfonyl)-2-O-(triisopropylsilyl)-α-D-lyxopyranoside (**37**). An ice-cold soln. of **17** (353 mg, 1.07 mmol) in pyridine (2 ml) was treated dropwise with MsCl (160 μl, 2.06 mmol), warmed to 23° (*ca.* 2 h) and stirred for 20 h (disappearance of **17**). The mixture was diluted with AcOEt (30 ml), washed with 10% aq. HCl soln., H₂O (10 ml) and brine (5 ml), and dried (MgSO₄). Evaporation and FC (2 g of silica gel; AcOEt/hexane/ (3:15) gave **37** (389 mg, 89%). Colourless solid. *R*_f (hexane/AcOEt 3:17) 0.10. M.p. 73.1–73.8°. [*α*]_D²⁵ = –19.6 (*c* = 0.55, CHCl₃). IR (CHCl₃): 3015*w*, 2945*s*, 2892*m*, 2869*s*, 2250*w*, 1464*m*, 1412*w*, 1371*s*, 1351*m*, 1179*s*, 1166*m*, 1066*s*, 1044*m*, 1013*m*, 990*m*, 964*s*, 909*m*, 882*m*, 844*s*. ¹H-NMR (300 MHz, CDCl₃): 5.01 (*dd*, *J* = 11.1, 2.7, H–C(3)); 4.62 (*d*, *J* = 1.8, H–C(1)); 4.26 (*t*, *J* ≈ 2.4, H–C(2)); 3.97 (*dd*, *J* = 11.1, 5.1, H_{eq}–C(5)); 3.86 (*t*, *J* ≈ 11.1, H_{ax}–C(5)); 3.48 (*td*, *J* ≈ 11.4, 5.4, H–C(4)); 3.39 (*s*, MeO); 3.18 (*s*, MsO); 1.29–1.06 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 117.21 (*s*, C≡N); 101.60 (*d*, C(1)); 76.05 (*d*, C(3)); 69.24 (*d*,

C(2)); 59.19 (*t*, C(5)); 55.67 (*q*, MeO); 38.83 (*q*, MsO); 29.14 (*d*, C(4)); 18.15 (*q*, (Me₂CH)₃Si); 12.62 (*d*, (Me₂CH)₃Si). Anal. calc. for C₁₇H₃₃NO₆SSi (407.598): C 50.09, H 8.16, N 3.44; found: C 50.21, H 8.03, N 3.40.

Methyl 4-[1-[(tert-Butoxy)carbonyl]-1H-imidazol-2-yl]-4-deoxy-2-O-(triisopropylsilyl)-α-D-lyxopyranoside (39). A soln. of **27** (1.288 g, 3.48 mmol) in anh. MeCN (12 ml) was treated with Boc₂O (987 mg, 4.5 mmol) and DMAP (47 mg, 0.385 mmol). The mixture was stirred at 24° for 4 h (disappearance of **27**), and evaporated. A soln. of the residue in AcOEt (30 ml) was washed with H₂O (10 ml) and brine (10 ml), dried (Na₂SO₄), and evaporated. The resulting thick oil was used for the next step without further purification. An anal. sample of **39** was obtained by FC (silica gel; hexane/AcOEt 4:1). Colourless oil. *R*_f (hexane/AcOEt 7:3) 0.42. [α]_D²⁵ = +20.5 (*c* = 0.7, CHCl₃). IR (CHCl₃): 3556w, 2945s, 2868m, 1750s, 1465m, 1414m, 1372m, 1307s, 1264w, 1142s, 1068s, 1021s, 971w, 908s. ¹H-NMR (300 MHz, CDCl₃): 7.28 (*d*, *J* = 1.8, H–C(5')); 6.88 (*d*, *J* = 1.8, irradi. at 7.29 → *s*, H–C(4')); 4.68 (*d*, *J* = 1.8, irradi. at 4.09 → *s*, H–C(1)); 4.26–4.18 (*m*, addn. of D₂O → change, irradi. at 3.97 → change, H–C(3), H–C(4)); 4.09 (*t*, *J* ≈ 2.2, irradi. at 4.68 → *d*, *J* = 2.4, irradi. at 4.20 → br. *s*, H–C(2)); 3.97 (*t*, *J* ≈ 10.8, irradi. at 4.20 → *d*, *J* = 10.8, H_{ax}–C(5)); 3.81 (*dd*, *J* = 10.8, 3.6, irradi. at 4.20 → *d*, *J* = 10.8, irradi. at 3.97 → change, H_{eq}–C(5)); 3.36 (*s*, MeO); 2.81 (*d*, *J* = 9.3, irradi. at 4.20 → br. *s*, exchanged with D₂O, HO–C(3)); 1.60 (*s*, Me₃C); 1.14–1.08 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 149.07 (*s*, C=O); 148.26 (*s*, C(2')); 127.68 (*d*, C(4')); 118.72 (*d*, C(5')); 102.04 (*d*, C(1)); 85.68 (*s*, Me₃C); 71.18, 70.93 (2*d*, C(2), C(3)); 61.68 (*t*, C(5)); 55.02 (*q*, MeO); 38.59 (*d*, C(4)); 28.01 (*q*, Me₃C); 18.20, 18.18 (2*q*, (Me₂CH)₃Si); 12.74 (*d*, (Me₂CH)₃Si). HR-MALDI-MS: 493.2700 ([*M* + Na]⁺, C₂₃H₄₂N₂NaO₆Si⁺; calc. 493.2704). Anal. calc. for C₂₃H₄₂N₂O₆Si (470.68): C 58.69, H 8.99, N 5.95; found: C 58.70, H 8.94, N 5.85.

Oxidation of 39 with Periodinane. At 3°, a soln. of **39** (1.2 g of crude product, 3.48 mmol) in anh. CH₂Cl₂ (8 ml) was treated with Dess–Martin's periodinane (1.24 g, 2.91 mmol). The mixture was stirred until disappearance of **39** (ca. 3–4 h), diluted with Et₂O (50 ml), and treated with sat. aq. NaHCO₃ soln. (20 ml). The aq. layer was washed with Et₂O (50 ml). The combined org. layers were washed with sat. aq. NaHCO₃ soln. (3 × 20 ml), dried (Na₂SO₄), and evaporated. FC (22 g of silica gel; hexane/AcOEt 4:1) gave **40** (975 mg, 60% from **27**) and a mixture of **40** and **41** (522 mg, 32% from **27**).

Methyl 4-[1-[(tert-Butoxy)carbonyl]-1H-imidazol-2-yl]-4-deoxy-2-O-(triisopropylsilyl)-α-D-threo-pentopyranosid-3-ulose (40). Colourless solid. *R*_f (hexane/AcOEt 7:3) 0.45. M.p. 83.8–85.1°. [α]_D²⁵ = +64.1 (*c* = 1.0, CHCl₃). IR (3%, CHCl₃): 2945s, 2868m, 1761s, 1741s, 1542w, 1499w, 1465m, 1412m 1372s, 1339s, 1309s, 1264w, 1165s, 1141s, 1066s, 1044s, 1004m, 941w, 883m, 844m. ¹H-NMR (300 MHz, CDCl₃; assignment based on a DQFQCOSY and a HSQC spectrum): 7.32 (*d*, *J* = 1.8, H–C(5')); 6.90 (*d*, *J* = 1.8, H–C(4')); 5.27 (*dd*, *J* = 11.1, 6.6, H–C(4)); 4.87 (*d*, *J* = 2.4, H–C(1)); 4.53 (*t*, *J* ≈ 11.0, H_{ax}–C(5)); 4.28 (*dd*, *J* = 11.1, 6.6, H_{eq}–C(5)); 4.11 (*d*, *J* = 1.8, H–C(2)); 3.41 (*s*, MeO); 1.54 (*s*, Me₃C); 1.19–1.13 (*m*, (Me₂CH)₃Si); 1.11, 1.09 (2*d*, *J* = 6.6, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 201.12 (*s*, C(3)); 148.25 (*s*, C(2')); 147.18 (*s*, OC=O); 127.76 (*d*, C(4')); 118.71 (*d*, C(5')); 104.76 (*d*, C(1)); 85.08 (*s*, Me₃C); 76.67 (*d*, C(2)); 62.57 (*t*, C(5)); 55.15 (*q*, MeO); 47.80 (*d*, C(4)); 27.92 (*q*, Me₃C); 18.04 (br. *q*, (Me₂CH)₃Si); 12.27 (*d*, (Me₂CH)₃Si). HR-MALDI-MS: 492.2587 ([*M* + Na]⁺, C₂₃H₄₀N₂NaO₆Si⁺; calc. 492.2593). Anal. calc. for C₂₃H₄₀N₂O₆Si (468.66): C 58.94, H 8.60, N 5.98; found: C 58.89, H 8.44, N 5.92.

Methyl 4-[1-[(tert-Butoxy)carbonyl]-1H-imidazol-2-yl]-4-deoxy-2-O-(triisopropylsilyl)-β-D-erthyro-pentopyranosid-3-ulose (41). Colourless oil. *R*_f (hexane/AcOEt 4:1) 0.15. [α]_D²⁵ = –14.3 (*c* = 0.2, CHCl₃). IR (CHCl₃): 2945m, 2892m, 2868m, 1758s, 1603w, 1544w, 1465m, 1413m 1372m, 1340m, 1309s, 1261w, 1139s, 1116s, 1104s, 1070m, 1020m, 997w, 969w, 919w, 884m, 844w. ¹H-NMR (300 MHz, CDCl₃): 7.34 (*d*, *J* = 1.8, H–C(5')); 6.87 (*d*, *J* = 1.8, H–C(4')); 4.63 (*dd*, *J* = 11.4, 6.6, H–C(4)); 4.51 (*dd*, *J* = 11.4, 6.3, H_{eq}–C(5)); 4.34 (*d*, *J* = 7.5, H–C(1)); 4.30 (*d*, *J* = 7.5, H–C(2)); 4.13 (*t*, *J* ≈ 11.4, H_{ax}–C(5)); 3.59 (*s*, MeO); 1.54 (*s*, Me₃C); 1.19–1.13 (*m*, (Me₂CH)₃Si). ¹³C-NMR (75 MHz, CDCl₃): 200.62 (*s*, C(3)); 147.18 (*s*, OC=O); 143.53 (*s*, C(2')); 127.76 (*d*, C(4')); 118.95 (*d*, C(5')); 107.40 (*d*, C(1)); 85.44 (*s*, Me₃C); 70.78 (*d*, C(2)); 63.65 (*t*, C(5)); 57.15 (*q*, MeO); 51.28 (*d*, C(4)); 27.93 (*q*, Me₃C); 18.02, 17.94 (2*q*, (Me₂CH)₃Si); 12.57 (*d*, (Me₂CH)₃Si). HR-MALDI-MS: 492.2587 ([*M* – Boc + Na]⁺, C₂₃H₄₀N₂NaO₆Si⁺; calc. 492.2593).

Methyl 4-[1-[(tert-Butoxy)carbonyl]-1H-imidazol-2-yl]-4-deoxy-2-O-(triisopropylsilyl)-α-D-arabinopyranoside (42). a) At 3–5°, a soln. of **40** (975 mg, 2.08 mmol) in dry MeOH (10 ml) was treated with NaBH₄ (38 mg, 1.03 mmol). The mixture was stirred for 1 h (disappearance of **40**), treated with sat. aq. NH₄Cl soln. (10 ml), and evaporated. The aq. residue was diluted with AcOEt (100 ml). The org. layer was separated, washed with H₂O (20 ml) and brine (20 ml), dried (Na₂SO₄), and evaporated. FC (ca. 23 g of silica gel; hexane/AcOEt 7:3) gave **39** (469 mg, 48%), **42** (265 mg, 25%), and an inseparable mixture (240 mg, 25%).

b) At 0°, a soln. of **40** (155 mg, 0.33 mmol) in dry MeOH (2 ml) was treated with CeCl₃·7 H₂O (130 mg, 0.35 mmol) and NaBH₄ (8.6 mg, 0.23 mmol), stirred for 20 min (disappearance of **40**), treated with sat. aq. NH₄Cl soln. (10 ml), and diluted with AcOEt (60 ml). The org. layer was separated, washed with brine (5 ml),

dried (Na_2SO_4), and evaporated. FC (3 g of silica gel, hexane/AcOEt 7:3) provided **42** (124 mg, 80%). Colourless oil. R_f (hexane/AcOEt 7:3) 0.34. $[\alpha]_D^{25} = -52.1$ ($c = 1.0$, EtOH). IR (CHCl_3): 3507w, 3342w, 2945m, 2868m, 1762s, 1602w, 1542w, 1464w, 1373m, 1305s, 1141s, 1101m, 1073w, 1038m, 882w. $^1\text{H-NMR}$ (300 MHz, CDCl_3 ; assignment based on a DQF-COSY and a HSQC spectrum): 7.34 (d , $J = 1.8$, $\text{H-C}(5')$); 6.86 (d , $J = 1.8$, $\text{H-C}(4')$); 4.95 (d , $J = 5.4$, exchanged with D_2O , $\text{HO-C}(3)$); 4.63 (br. s, $\text{H-C}(1)$); 4.29 (t , $J \approx 11.8$, irradi. at 3.70 $\rightarrow$ change, $\text{H}_{\text{ax}}-\text{C}(5)$); 4.28–4.22 (overlapped m , addn. of $\text{D}_2\text{O} \rightarrow$ change, $\text{H-C}(3)$); 4.15 (ddd , $J \approx 11.1$, 4.0, 2.1, irradi. at 3.70 $\rightarrow$ change, $\text{H-C}(4)$); 3.95 (dd , $J = 3.0$, 1.2, irradi. at 4.63 $\rightarrow$ d , $J = 3.3$, $\text{H-C}(2)$); 3.70 (ddd , $J \approx 10.8$, 4.0, 1.2, $\text{H}_{\text{eq}}-\text{C}(5)$); 3.39 (s , MeO); 1.62 (s , Me_3C); 1.08 (br. s, $(\text{Me}_2\text{CH})_3\text{Si}$). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 149.10 (s , OC=O); 147.27 (s , $\text{C}(2')$); 127.11 (d , $\text{C}(4')$); 118.69 (d , $\text{C}(5')$); 101.88 (d , $\text{C}(1)$); 85.82 (s , Me_3C); 70.10 (d , $\text{C}(2)$); 69.14 (d , $\text{C}(3)$); 59.96 (t , $\text{C}(5)$); 55.85 (q , MeO); 36.10 (d , $\text{C}(4)$); 27.99 (q , Me_3C); 18.21, 18.06 ($2q$, $(\text{Me}_2\text{CH})_3\text{Si}$); 12.40 (d , $\text{Me}_2\text{CH}_3\text{Si}$). HR-MALDI-MS: 493.2700 ($[M + \text{Na}]^+$, $\text{C}_{23}\text{H}_{42}\text{O}_6\text{N}_2\text{NaSi}^+$; calc. 493.2710). Anal. calc. for $\text{C}_{23}\text{H}_{42}\text{N}_2\text{O}_6\text{Si} \cdot 0.25 \text{H}_2\text{O}$ (475.18): C 58.14, H 9.04, N 5.90; found: C 57.96, H 8.57, N 5.73.

Methyl 3-O-[(tert-Butoxy)carbonyl]-4-deoxy-4-(1H-imidazol-2-yl)-2-O-(triisopropylsilyl)- α -D-arabinopyranoside (43). A soln. of **42** (17 mg, 0.36 mmol) in dry MeOH/Et₃N 10:1 (1.1 ml) was stirred at 23° for 5 h (disappearance of **42**) and evaporated. FC (5 g of silica gel, hexane/AcOEt 7:3) gave **43** (12 mg, 71%). Colourless solid. M.p. 124.8–126.2°. R_f (hexane/AcOEt 7:3) 0.45. $[\alpha]_D^{25} = -32.9$ ($c = 0.30$, CHCl_3). IR (CHCl_3): 3246w, 2962m, 2946m, 2868m, 1744s, 1545w, 1464m, 1395w, 1370w, 1280s, 1262s, 1130s, 1099s, 1080s, 1040s, 999s, 919w, 882m, 846m, 821m. $^1\text{H-NMR}$ (300 MHz, CDCl_3 ; assignment based on a DQF-COSY and a HSQC spectrum): 7.00 (br. s, $\text{H-C}(4')$); 6.96 (br. s, $\text{H-C}(5')$); 4.85 (dd , $J = 6.0$, 4.2, irradi. at 3.85 $\rightarrow$ change, $\text{H-C}(3)$); 4.40 (d , $J = 4.5$, irradi. at 3.85 $\rightarrow$ s , $\text{H-C}(1)$); 4.25 (dd , $J = 10.6$, 6.0, irradi. at 3.75 $\rightarrow$ change, $\text{H}_{\text{ax}}-\text{C}(5)$); 3.85 (dd , $J = 6.0$, 4.5, irradi. at 4.40 $\rightarrow$ d , $J = 6.0$, irradi. at 4.85 $\rightarrow$ d , $J = 4.5$, $\text{H-C}(2)$); 3.83 (dt , $J = 6.0$, 4.2, $\text{H-C}(4)$); 3.78 (dd , $J = 10.6$, 4.2, $\text{H}_{\text{eq}}-\text{C}(5)$); 3.46 (s , MeO); 1.45 (s , Me_3C); 1.08–1.04 (m , $(\text{Me}_2\text{CH})_3\text{Si}$). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3 ; assignment based on a DQF-COSY and a HSQC spectrum): 152.80 (s , OC=O); 144.96 (s , $\text{C}(2')$); 128.22 (d , $\text{C}(4')$); 115.80 (d , $\text{C}(5')$); 103.50 (d , $\text{C}(1)$); 82.80 (s , Me_3C); 75.59 (d , $\text{C}(3)$); 69.67 (d , $\text{C}(2)$); 60.81 (t , $\text{C}(5)$); 56.39 (q , MeO); 36.94 (d , $\text{C}(4)$); 27.84 (q , Me_3C); 18.10 (q , $(\text{Me}_2\text{CH})_3\text{Si}$); 12.37 (d , $(\text{Me}_2\text{CH})_3\text{Si}$). HR-MALDI-MS: 471.2875 ($[M + \text{H}]^+$, $\text{C}_{23}\text{H}_{43}\text{N}_2\text{O}_6\text{Si}^+$; calc. 471.2885). Anal. calc. for $\text{C}_{23}\text{H}_{42}\text{N}_2\text{O}_6\text{Si}$ (470.68): C 58.69, H 8.99, N 5.95; found: C 58.94, H 9.07, N 5.90.

Methyl 4-[1-[(tert-Butoxy)carbonyl]-1H-imidazol-2-yl]-4-deoxy-2-O-(triisopropylsilyl)- β -D-xylopyranoside (44). A cold soln. of **41** (70 mg, 0.15 mmol) in dry MeOH (2 ml) was treated with NaBH_4 (6.5 mg, 0.17 mmol). The mixture was stirred for 1 h (disappearance of **41**), treated with sat. aq. NH_4Cl soln. (1 ml), and evaporated. The aq. residue was diluted with AcOEt (20 ml). The org. layer was separated and washed with H_2O (5 ml) and brine (5 ml), dried (Na_2SO_4), and evaporated. FC (ca. 6 g of silica gel, hexane/AcOEt 17:3) gave **44** (38 mg, 54%). Colourless oil. R_f (hexane/AcOEt 7:3) 0.45. $[\alpha]_D^{25} = +57.8$ ($c = 0.47$, CHCl_3). IR (CHCl_3): 3588w, 3018w, 2962m, 2945m, 2867m, 1760m, 1463w, 1372m, 1353w, 1306s, 1262m, 1140s, 1099m, 1071m, 1034m, 988w, 908w, 883m, 842m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 7.32 (d , $J = 1.8$, $\text{H-C}(5')$); 6.91 (d , $J = 1.8$, $\text{H-C}(4')$); 4.20 (ddd , $J = 10.5$, 8.7, 3.6, irradi. at 3.83 $\rightarrow$ change, irradi. at 3.59 $\rightarrow$ change, irradi. at 2.78 $\rightarrow$ dd , $J = 10.5$, 8.7, addn. of $\text{CD}_3\text{OD} \rightarrow$ dd , $J = 10.5$, 8.7, $\text{H-C}(3)$); 4.17 (d , $J = 7.5$, irradi. at 3.59 $\rightarrow$ change, $\text{H-C}(1)$); 4.13 (dd , $J = 11.1$, 4.2, irradi. at 3.80 $\rightarrow$ change, $\text{H}_{\text{ax}}-\text{C}(5)$); 3.80 (td , $J \approx 10.5$, 4.2, $\text{H-C}(4)$); 3.59 (dd , $J = 8.7$, 7.5, $\text{H-C}(2)$); 3.49 (s , MeO); 3.47 (dd , $J = 11.1$, 10.8, irradi. at 3.80 $\rightarrow$ change $\text{H}_{\text{ax}}-\text{C}(5)$); 2.78 (d , $J = 3.6$, exchanged with CD_3OD , $\text{HO-C}(3)$); 1.61 (s , Me_3C); 1.18–1.05 (m , $(\text{Me}_2\text{CH})_3\text{Si}$). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 147.69, 147.20 ($2s$, C=O , $\text{C}(2')$); 127.74 (d , $\text{C}(4')$); 119.13 (d , $\text{C}(5')$); 105.46 (d , $\text{C}(1)$); 86.0 (s , Me_3C); 76.63, 75.13 (d , $\text{C}(2)$, $\text{C}(3)$); 65.01 (t , $\text{C}(5)$); 56.78 (q , MeO); 43.22 (d , $\text{C}(4)$); 27.94 (q , Me_3C); 18.26, 18.21 ($2q$, $(\text{Me}_2\text{CH})_3\text{Si}$); 12.73 (d , $(\text{Me}_2\text{CH})_3\text{Si}$). HR-MALDI-MS: 493.2587 ($[M + \text{Na}]^+$, $\text{C}_{23}\text{H}_{42}\text{N}_2\text{NaO}_6\text{Si}^+$; calc. 493.2593).

(5R,6S,7R,8R)- and (5S,6S,7R,8R)-5,6,7,8-Tetrahydro-8-(hydroxymethyl)-imidazo[1,2-a]pyridine-5,6,7-triol (5 and 45, resp.). A soln. of **42** (365 mg, 0.78 mmol) in 80% aq. AcOH (6.8 ml) was treated with 20% aq. HCl (1.15 ml, ca. 2.3 mmol). The stirred mixture was kept for 2.5 h at 113° and evaporated. FC (9 g of silica gel; AcOEt/MeOH/ H_2O 13:6:1) and filtration through Amberlite-CG-120 (H^+ form, 2% aq. NH_4OH) gave **5/45** (182 mg, 95%). Light yellow hygroscopic solid. M.p. 180–185° (dec.). $^1\text{H-NMR}$ (300 MHz, CD_3OD ; **5/45** 47:53, > 95% pure): 7.14 (d , $J = 1.2$, 0.47 H), 7.10 (d , $J = 1.5$, 0.53 H) ($\text{H-C}(2)$); 6.97 (d , $J = 1.5$, 0.53 H- $\text{C}(3)$); 6.89 (d , $J = 1.2$, 0.47 H- $\text{C}(3)$); 5.89 (d , $J = 3.6$, 0.53 H- $\text{C}(5)$); 5.15 (d , $J = 7.2$, 0.47 H- $\text{C}(5)$); 4.27 (dd , $J = 8.4$, 7.5, irradi. at 2.83 $\rightarrow$ change, 0.53 H, $\text{H-C}(7)$); 4.24 (dd , $J = 10.8$, 3.6, irradi. at 2.83 $\rightarrow$ change, 0.53 H), 4.17 (dd , $J = 10.5$, 3.9, irradi. at 2.83 $\rightarrow$ change, 0.53 H), 4.08 (br. dd , $J = 9.6$, 3.6, irradi. at 2.83 $\rightarrow$ change, 0.47 H), 4.04 (dd , $J = 10.5$, 3.9, irradi. at 2.83 $\rightarrow$ change, 0.47 H) ($\text{CH}_2-\text{C}(8)$); 3.93 (t , $J = 9.3$, 0.47 H- $\text{C}(7)$); 3.85 (dd , $J = 8.7$, 3.6, irradi. at 5.89 $\rightarrow$ d , $J = 8.7$, 0.53 H- $\text{C}(6)$); 3.64 (dd , $J = 9.6$, 7.2, 0.47 H- $\text{C}(6)$); 2.97–2.79 (m , $\text{H-C}(8)$).

Data for 5/45·HCl: Hygroscopic solid. R_f (AcOEt/MeOH/ H_2O 13:6:1) 0.52. $[\alpha]_D^{25} = -52.1$ ($c = 1.0$, EtOH). IR (KBr): 3400w, 2936m, 1634s, 1535s, 1490m, 1461m, 1376m, 1325m, 1267m, 1176w, 1131s, 1090s,

1067s, 1004m, 938w, 903w, 814w. $^1\text{H-NMR}$ (300 MHz, CD_3OD ; **5/45** ca. 1:1): 7.22, 7.21 (2d, $J = 1.5$, H–C(2)); 7.04, 7.03 (2d, $J = 1.5$, H–C(3)); 5.72 (d, $J = 3.6$, 0.5 H, H–C(5) of **45**); 5.26 (d, $J = 6.6$, 0.5 H, H–C(5) of **5**); 4.26 (dd, $J = 11.4$, 3.3, 0.5 H, H–C(7) of **45**); 4.21 (dd, $J = 12.1$, 3.3, 0.5 H, $\text{CH}_a\text{–C}(8)$ of **45**); 4.10 (t, $J \approx 9.0$, 0.5 H, H–C(7) of **5**); 3.98–3.90 (m, 1 H), 3.81–3.70 (m, 1.5 H), ($\text{CH}_b\text{–C}(8)$ of **45**, $\text{CH}_2\text{–C}(8)$ of **5**, H–C(6)); 3.04–2.97 (m, H–C(8)). $^{13}\text{C-NMR}$ (75 MHz, CD_3OD ; **5/45** ca. 1:1): 145.95, 145.30 (2s, C(8a)); 128.58, 128.48 (2d, C(2)); 119.34, 117.81 (2d, C(3)); 82.44 (d, C(5) of **45**); 78.40 (d, C(5) of **5**); 76.53 (d, C(6) of **45**); 72.39 (d, C(6) of **5**); 71.84, 70.93, 70.79, 68.83 (4d, C(2), C(3)); 69.70, 67.55 (2d, C(7)); 62.47, 61.78 (2t, $\text{CH}_2\text{–C}(8)$); 45.05, 44.95 (2d, C(8)). HR-MS-MALDI: 201.0872 ($[M + \text{H} - \text{HCl}]^+$, $\text{C}_8\text{H}_{15}\text{O}_4\text{N}_2^+$; calc. 201.0870).

4-Deoxy-4-(1H-imidazol-2-yl)-D-arabinitol (46). A cold soln. of **5/45** (43 mg, 0.18 mmol) in MeOH (2 ml) was treated at 0° with AcOH (0.2 ml) and NaCNBH_3 (41 mg, 0.65 mmol), warmed to 28° , stirred at that temp. for 60 h, and co-evaporated with toluene. FC (AcOEt/MeOH/25% aq. NH_4OH 14:5:1) gave slightly impure **46**, which, upon additional FC (AcOEt/MeOH/25% NH_4OH , 7:2:1), gave **46**·HOAc (22 mg, 66%). Hygroscopic solid. $[\alpha]_D^{25} = -2.9$ ($c = 0.1$, EtOH). R_f (AcOEt/MeOH/25% aq. NH_4OH , 7:2:1) 0.26. IR (KBr): 3427s, 2925w, 2558w, 1666s, 1624s, 1442m, 1366s, 1032w, 1047w, 998w, 834s. $^1\text{H-NMR}$ (300 MHz, CD_3OD , **46**·HOAc): 7.11 (br. s, H–C(4')), H–C(5')); 3.95–3.85 (m, 2 H–C(1)); 3.93 (dd, $J = 9.0$, 1.8, irradi. at 3.04 $\rightarrow$ dd, $J = 9.0$, H–C(3)); 3.48 (dd, $J = 10.8$, 6.0, $\text{H}_a\text{–C}(5)$); 3.41 (dd, $J = 10.8$, 6.0, irradi. at 3.04 $\rightarrow$ change, $\text{H}_b\text{–C}(5)$); 3.34 (ddd, $J \approx 9.0$, 6.3, 5.1, H–C(2)); 3.04 (td, $J = 6.0$, 1.8, H–C(4)); 1.83 (s, AcO). $^{13}\text{C-NMR}$ (75 MHz, CD_3OD , **46**·HOAc): 179.31 (s, C=O); 148.40 (s, C(1')); 121.06 (d, C(4'), C(5')); 72.97, 71.33 (2d, C(2), C(3)); 64.56, 63.32 (2t, C(1), C(5)); 45.83 (d, C(4)); 22.95 (q, Me). ESI-MS: 203.3 ($[M + \text{H}]^+$, $\text{C}_8\text{H}_{15}\text{N}_2\text{O}_4^+$; calc. 203.3).

Silylation of 5/45. At 2° , a soln. of **5/45** (31 mg, 0.131 mmol) in dry pyridine (2.5 ml) was treated with 2,6-lutidine (0.07 ml) and Et_3SiCl (0.2 ml), stirred for 46 h at 26° , diluted with AcOEt (25 ml), washed with H_2O (2×5 ml) and brine (5 ml), dried (Na_2SO_4), and evaporated. FC (3 g of silica gel; ca. 50 ml of AcOEt/hexane 1:9) gave **47/48** ca. 1:4 (14 mg, 16%) and **47/48** ca. 85:17 (27 mg, 31%).

(**5S,6S,7R,8R**)-5,6,7,8-Tetrahydro-5,6,7-tris(triethylsilyloxy)-8-[(triethylsilyloxy)methyl]imidazo[1,2-a]pyridine (**48**): Data for a ca. 1:4 Mixture **47/48**. Colourless oil. R_f (hexane/AcOEt 9:1) 0.31. $[\alpha]_D^{25} = +8.5$ ($c = 0.6$, CHCl_3). IR (CHCl_3): 2958s, 2913s, 2878s, 1526w, 1485w, 1458m, 1414m 1378w, 1259w, 1094w, 1007s, 973w, 921w, 887w, 833m. $^1\text{H-NMR}$ (300 MHz, CDCl_3 ; **47/48** ca. 1:4): 7.00 (d, $J = 1.5$, H–C(2)); 6.92 (d, $J = 1.2$, H–C(3)); 5.42 (dd, $J = 1.8$, 0.9, irradi. at 4.49 $\rightarrow$ d, $J = 1.8$, H–C(5)); 4.49 (ddd, $J \approx 3.6$, 1.2, 0.9, irradi. at 5.42 $\rightarrow$ dd, $J = 3.3$, 1.2, H–C(7)); 4.07 (dd, $J = 3.6$, 1.8, irradi. at 5.42 $\rightarrow$ d, $J = 3.9$, irradi. at 4.49 $\rightarrow$ d, $J = 1.8$, H–C(6)); 4.07 (dd, $J = 9.6$, 5.4, $\text{CH}_a\text{–C}(8)$); 3.75 (dd, $J = 11.0$, 9.6, irradi. at 4.07 $\rightarrow$ d, $J \approx 11.0$, $\text{CH}_b\text{–C}(8)$); 3.20 (ddd, $J = 10.5$, 5.1, 0.5, irradi. at 4.49 $\rightarrow$ dd, $J = 10.5$, 5.4, irradi. at 4.07 $\rightarrow$ dd, $J = 10.5$, 0.5, H–C(8)); 1.04–0.55 (m, 4 (MeCH_2)₃Si). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3 ; **47/48** ca. 1:4): 143.13 (s, C(8a)); 128.50 (d, C(2)); 117.59 (d, C(3)); 81.61 (d, C(5)); 73.94 (d, C(7)); 67.99 (d, C(6)); 64.02 (t, $\text{CH}_2\text{–C}(8)$); 46.19 (d, C(8)); 7.14, 7.06, 6.97 (3q, 4 (MeCH_2)₃Si); 5.09, 4.87, 4.60 (3t, 4 (MeCH_2)₃Si). HR-MALDI-MS: 657.4335 ($[M + \text{H}]^+$, $\text{C}_{32}\text{H}_{69}\text{N}_2\text{O}_4\text{Si}_4^+$; calc. 657.4329).

(**5S,6S,7R,8R**)-5,6,7,8-Tetrahydro-5,6,7-tris(triethylsilyloxy)-8-[(triethylsilyloxy)methyl]imidazo[1,2-a]pyridine (**47**): Data for a 85:15 Mixture **47/48**. Colourless oil. R_f (hexane/AcOEt 9:1) 0.26. $[\alpha]_D^{25} = -15.1$ ($c = 1.3$, CHCl_3). IR (CHCl_3): 3017w, 2958s, 2913s, 2878s, 1458w, 1414w, 1354w, 1264w, 1154m, 1092w, 1007m, 967w, 919w, 829m. $^1\text{H-NMR}$ (300 MHz, CDCl_3 ; **47/48** ca. 85:15): 6.99 (d, $J = 1.25$, H–C(2)); 6.92 (d, $J = 1.25$, H–C(3)); 5.70 (d, $J = 1.8$, H–C(5)); 4.51 (dd, $J = 5.1$, 1.2, irradi. at 2.98 $\rightarrow$ d, $J = 5.1$, H–C(7)); 4.18 (dd, $J = 9.6$, 5.1, irradi. at 2.98 $\rightarrow$ d, $J \approx 9.6$, $\text{CH}_a\text{–C}(8)$); 3.95 (dd, $J = 5.1$, 1.8, irradi. at 5.70 $\rightarrow$ d, $J = 5.1$, irradi. at 4.51 $\rightarrow$ d, $J = 1.8$, H–C(6)); 3.78 (dd, $J = 10.5$, 9.6, irradi. at 2.98 $\rightarrow$ dd, $J = 10.5$, $\text{CH}_b\text{–C}(8)$); 2.98 (ddd, $J = 10.5$, 5.1, 1.2, irradi. at 4.18 $\rightarrow$ br. d, $J = 10.5$, H–C(8)); 1.06–0.52 (m, 4 (MeCH_2)₃Si). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3 ; **47/48** ca. 85:15): 143.71 (s, C(8a)); 127.56 (d, C(3)); 115.00 (d, C(4)); 78.37 (d, C(5)); 74.24 (d, C(7)); 68.06 (d, C(6)); 64.26 (t, $\text{CH}_2\text{–C}(8)$); 46.28 (d, C(8)); 7.03, 6.87 (2q, 4 (MeCH_2)₃Si); 5.05, 4.86, 4.55 (3t, 4 (MeCH_2)₃Si). HR-MALDI-MS: 657.4319 ($[M + \text{H}]^+$, $\text{C}_{32}\text{H}_{69}\text{N}_2\text{O}_4\text{Si}_4^+$; calc. 657.4329).

Inhibition Studies. IC_{50} Values were determined at a substrate concentration near K_M value of the each enzyme by plotting the reciprocal value of the rate of substrate hydrolysis vs. the inhibitor concentration. After fitting a straight line to the data by linear regression, the negative $[I]$ -intercept of this plot provided the appropriate IC_{50} value.

a) **Inhibition of Escherichia coli β -Galactosidase.** $K_M = 0.94$ mM ($[70]$: 0.18 mM). The assay was carried out at pH 6.9 ($\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ buffer 100 mM) and at 37° . The reaction was started by addition of 2-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 15 min at 37° . After 20 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

b) *Inhibition of Bovine Liver β -Galactosidase.* $K_M = 1.45$ mM. The assay was carried out at pH 6.9 ($\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ buffer 100 mM) and at 37°. The reaction was started by addition of 2-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 20 min at 50°. After 30 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

c) *Inhibition of A. oryzae β -Galactosidase.* $K_M = 2.5$ mM. The assay was carried out at pH 4.9 (AcONa buffer 50 mM) and at 30°. The reaction was started by addition of 2-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 10 min at 30°. After 30 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

d) *Inhibition of Caldocellum saccharolyticum β -Glucosidase.* $K_M = 1.95$ mM ([71]: 0.51 mM). The assay was carried out at pH 4.9 (AcONa buffer 50 mM) and at 55°. The reaction was started by addition of 4-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 10 min at 55°. After 20 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

e) *Inhibition of Sweet Almond β -Glucosidases.* $K_M = 3.2$ mM ([72]: 67–80 mM at pH 5.2–6.0). The assay was carried out at pH 6.9 ($\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ buffer 100 mM) and at 37°. The reaction was started by addition of 4-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 10 min at 37°. After 30 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

f) *Inhibition of T. reesei Cellulase Cel7A.* $K_M = 0.63$ – 0.88 mM ([73]: 0.46 mM). The assay was carried out at pH 4.9 (AcONa buffer 50 mM) and at 50°. The reaction was started by addition of 4-nitrophenyl β -D-galactopyranoside after preincubating the enzyme in the presence of the inhibitor for 10 min at 50°. After 25 min, the reaction was quenched by the addition of 400 mM Na_2CO_3 soln. The rate of hydrolysis was determined by measuring the absorption at λ 405 nm and subsequently subtracting the absorption of a blank probe (H_2O , buffer, and substrate).

REFERENCES

- [1] T. D. Heightman, A. T. Vasella, *Angew. Chem., Int. Ed.* **1999**, 38, 750.
- [2] T. Granier, N. Panday, A. Vasella, *Helv. Chim. Acta* **1997**, 80, 979.
- [3] N. Panday, T. Granier, A. Vasella, *Helv. Chim. Acta* **1998**, 81, 475.
- [4] N. Panday, A. Vasella, *Synthesis* **1999**, 1459.
- [5] N. Panday, A. Vasella, *Helv. Chim. Acta* **2000**, 83, 1205.
- [6] N. Panday, M. Meyyappan, A. Vasella, *Helv. Chim. Acta* **2000**, 83, 513.
- [7] N. Panday, Y. Canac, A. Vasella, *Helv. Chim. Acta* **2000**, 83, 58.
- [8] M. Terinek, A. Vasella, *Helv. Chim. Acta* **2003**, 86, 3482.
- [9] K. Tatsuta, *Pure Appl. Chem.* **1996**, 68, 1341.
- [10] K. Tatsuta, S. Miura, H. Gunji, *Bull. Chem. Soc. Jpn.* **1997**, 70, 427.
- [11] K. Tatsuta, S. Miura, *Tetrahedron Lett.* **1995**, 36, 6721.
- [12] K. Tatsuta, S. Miura, S. Ohta, H. Gunji, *Tetrahedron Lett.* **1995**, 36, 1085.
- [13] K. Tatsuta, S. Miura, S. Ohta, H. Gunji, *J. Antibiot.* **1995**, 48, 286.
- [14] T. Aoyagi, H. Suda, K. Uotani, F. Kojima, T. Aoyama, K. Horiguchi, M. Hamada, T. Takeuchi, *J. Antibiot.* **1992**, 45, 1404.
- [15] T. Aoyama, H. Naganawa, H. Suda, K. Uotani, T. Aoyagi, T. Takeuchi, *J. Antibiot.* **1992**, 45, 1557.
- [16] M. Terinek, A. Vasella, *Helv. Chim. Acta* **2004**, 87, 3035.
- [17] M. Terinek, A. Vasella, *Helv. Chim. Acta* **2005**, 88, 10.
- [18] E. Dubost, T. Tschamber, J. Streith, *Tetrahedron Lett.* **2003**, 44, 3667.
- [19] A. Frankowski, C. Seliga, D. Bur, J. Streith, *Helv. Chim. Acta* **1991**, 74, 934.
- [20] A. Frankowski, D. Deredas, J. Streith, T. Tschamber, *Tetrahedron* **1998**, 54, 9033.
- [21] J. Streith, H. Rudyk, T. Tschamber, C. Tarnus, C. Strehler, D. Deredas, A. Frankowski, *Eur. J. Org. Chem.* **1999**, 893.

- [22] J. Streith, A. Boiron, A. Frankowski, D. Lenouen, H. Rudyk, T. Tschamber, *Synthesis* **1995**, 944.
- [23] F. Gessier, T. Tschamber, C. Tarnus, M. Neuburger, W. Huber, J. Streith, *Eur. J. Org. Chem.* **2001**, 4111.
- [24] K. Weinberg, S. Jankowski, D. Le Nouen, A. Frankowski, *Tetrahedron Lett.* **2002**, 43, 1089.
- [25] C. V. Ramana, A. Vasella, *Helv. Chim. Acta* **2000**, 83, 1599.
- [26] G. J. Davies, L. Mackenzie, A. Varrot, M. Dauter, A. M. Brzozowski, M. Schülein, S. G. Withers, *Biochemistry* **1998**, 37, 11707.
- [27] G. Sulzenbacher, H. Driguez, B. Henrissat, M. Schülein, G. J. Davies, *Biochemistry* **1996**, 35, 15280.
- [28] P. W. Kent, P. F. V. Ward, *J. Chem. Soc.* **1953**, 416.
- [29] J. P. Verheijden, P. J. Stoffyn, *Tetrahedron* **1957**, 1, 253.
- [30] C. V. Varaprasad, D. Averett, K. S. Ramasamy, *Tetrahedron* **1999**, 55, 13345.
- [31] J. G. Buchanan, R. Fletcher, K. Parry, W. A. Thomas, *J. Chem. Soc. B* **1969**, 377.
- [32] W. G. Overend, A. C. White, N. R. Williams, *Chem. Ind. (London)* **1963**, 1840.
- [33] T. Granier, A. Vasella, *Helv. Chim. Acta* **1995**, 78, 1738.
- [34] J. Sychala, *Synth. Commun.* **1997**, 27, 3431.
- [35] G. Levesque, J. C. Gressier, M. Proust, *Synthesis* **1981**, 963.
- [36] D. H. Hua, F. Q. Zhang, J. S. Chen, P. D. Robinson, *J. Org. Chem.* **1994**, 59, 5084.
- [37] W. Nagata, M. Yoshioka, T. Okumura, *J. Chem. Soc. C* **1970**, 2365.
- [38] A. Knierzinger, A. Vasella, *J. Chem. Soc., Chem. Commun.* **1984**, 9.
- [39] K. Sugita, A. Ohta, M. Onaka, Y. Izumi, *Chem. Lett.* **1990**, 481.
- [40] M. K. Dowd, W. M. Rockey, A. D. French, P. J. Reilly, *J. Carbohydr. Chem.* **2002**, 21, 11.
- [41] A. G. Evdokimov, F. Frolow, *Acta Crystallogr., Sect. C* **1996**, 52, 3218.
- [42] J. Alzeer, A. Vasella, *Helv. Chim. Acta* **1995**, 78, 177.
- [43] S. Patai, 'The Chemistry of Amidines and Imidates', John Wiley & Sons, London, 1975.
- [44] G. Rousselet, P. Capdevielle, M. Maumy, *Tetrahedron Lett.* **1993**, 34, 6395.
- [45] J. I. Ogonor, *Tetrahedron* **1981**, 37, 2909.
- [46] J. I. Levin, E. Turos, S. M. Weinreb, *Synth. Commun.* **1982**, 12, 989.
- [47] R. S. Garigipati, *Tetrahedron Lett.* **1990**, 31, 1969.
- [48] R. A. Moss, W. Ma, D. C. Merrer, S. Xue, *Tetrahedron Lett.* **1995**, 36, 8761.
- [49] D. B. Dess, J. C. Martin, *J. Am. Chem. Soc.* **1991**, 113, 7277.
- [50] S. V. Ley, J. Norman, W. P. Griffith, S. P. Marsden, *Synthesis* **1994**, 639.
- [51] A. J. Mancuso, D. Swern, *Synthesis* **1981**, 165.
- [52] O. Mitsunobu, *Synthesis* **1981**, 1.
- [53] J. L. Luche, *J. Am. Chem. Soc.* **1978**, 100, 2226.
- [54] S. P. Bew, S. D. Bull, S. G. Davies, E. D. Savory, D. J. Watkin, *Tetrahedron* **2002**, 58, 9387.
- [55] S. Knapp, P. J. Kukkola, S. Sharma, T. G. M. Dhar, A. B. J. Naughton, *J. Org. Chem.* **1990**, 55, 5700.
- [56] E. L. Eliel, H. Satici, *J. Org. Chem.* **1994**, 59, 688.
- [57] M. A. Tius, J. Busch-Petersen, *Tetrahedron Lett.* **1994**, 35, 5181.
- [58] T. Hosoya, Y. Ohashi, T. Matsumoto, K. Suzuki, *Tetrahedron Lett.* **1996**, 37, 663.
- [59] J. Xu, A. Egger, B. Bernet, A. Vasella, *Helv. Chim. Acta* **1996**, 79, 2004.
- [60] H. Yamada, M. Nakatani, T. Ikeda, Y. Marumoto, *Tetrahedron Lett.* **1999**, 40, 5573.
- [61] S. Shuto, M. Terauchi, Y. Yahiro, H. Abe, S. Ichikawa, A. Matsuda, *Tetrahedron Lett.* **2000**, 41, 4151.
- [62] S. Shuto, M. Terauchi, Y. Yahiro, H. Abe, S. Ichikawa, A. Matsuda, *Tetrahedron Lett.* **2004**, 45, 6819.
- [63] G. F. Painter, A. Falshaw, H. Wong, *Org. Biomol. Chem.* **2004**, 2, 1007.
- [64] R. H. Jacobson, X. J. Zhang, R. F. DuBose, B. W. Matthews, *Nature* **1994**, 369, 761.
- [65] M. Kurogochi, S. I. Nishimura, Y. C. Lee, *J. Biol. Chem.* **2004**, 279, 44704.
- [66] A. Varrot, C. A. Tarling, J. M. Macdonald, R. V. Stick, D. L. Zechel, S. G. Withers, G. J. Davies, *J. Am. Chem. Soc.* **2003**, 125, 7496.
- [67] S. Vonhoff, K. Piens, M. Pipelier, C. Braet, M. Claeysens, A. Vasella, *Helv. Chim. Acta* **1999**, 82, 963.
- [68] J. M. Macdonald, R. V. Stick, D. M. G. Tilbrook, S. G. Withers, *Aust. J. Chem.* **2002**, 55, 747.
- [69] V. Popsavin, S. Grabe, B. Stojanovic, M. Popsavin, V. Pejanovic, D. Milkjovic, *Carbohydr. Res.* **1999**, 312, 110.
- [70] S. A. Kuby, H. A. Lardy, *J. Am. Chem. Soc.* **1953**, 75, 890.
- [71] A. R. Plant, J. E. Oliver, M. L. Patchett, R. M. Daniel, H. W. Morgan, *Arch. Biochem. Biophys.* **1988**, 262, 181.
- [72] J. Schwartz, J. Sloan, *Arch. Biochem. Biophys.* **1970**, 137, 122.
- [73] J. Stahlberg, C. Divne, A. Koivula, K. Piens, M. Claeysens, T. T. Teeri, T. A. Jones, *J. Mol. Biol.* **1996**, 264, 337.

Received October 23, 2004